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Abstract 
Dendritic cells (DC) are an attractive target for both vaccine targeting and use as a 
delivery vehicle due to their ability to direct innate and adaptive immune responses. In 
this study a procedure was developed where DC were employed as a vehicle to induce 
cell-mediated immune responses to the Gram negative bacillus Burkholderia 
pseudomallei. This bacterium is the causative agent of melioidosis, a disease endemic 
to areas of south-east Asia and northern Australia, to which presently no licensed 
vaccine exists. 
Purified DC were pulsed with heat-killed (HK) whole cell B. pseudomallei and used to 
immunise syngeneic mice. The use of this immunisation method elicited strong cellular 
immune responses against B. pseudomallei, which have historically been difficult to 
generate. Antibody responses following immunisation with DC were low. Booster 
immunisations of either a second dose of HK B. pseudomallei pulsed DC or HK B. 
pseudomallei in MPL + TDM adjuvant were administered to increase the immune 
response. Immunised animals were challenged with fully virulent B. pseudomallei and 
protection was demonstrated in animals immunised with a combination of HK B. 
pseudomallei pulsed DC and HK B. pseudomallei delivered in MPL + TDM adjuvant. 
The protective immune response demonstrated was then further elucidated to reveal a 
role for both cell-mediated and humoral immunity in protection against B. pseudomallei 
infection. The data also demonstrate the potential for DC as vaccine delivery vectors 
and as a screening mechanism for the evaluation of potential vaccine candidates. 
xix 
Chapter J -Introduction 
Chapter 1 
Introduction 
Chapter 1 - lntroduction 
1.1 Genus Burkholderia 
1.1.1 The pseudomonads 
The pseudomonads are a major group of chemoorganotropic aerobic gram-negative rods 
with three important genera, Pseudomonas, Commamonas and Burkholderia. 
Phylogenetically, the various genera of pseudomonads scatter within the purple 
bacteria. They are thought to be derived from ancestral phototropic bacteria, which 
dispensed with the property of photosynthesis in evolving to colonise habitats where the 
ability to carry out anaerobic photosynthesis was not a significant advantage, such as in 
soil or on the surfaces of animals (132). 
The original description of the genus Burkholderia was in 1992 (234) for seven species 
belonging to the RNA homology group 11 of genus Pseudomonas: P. cepacia, P. mallei, 
P. pseudomallei, P. caryophyl/i, P. gladioli, P. pickettii and P. solanacearum. To date, 
42 species have been identified as belonging to the genus Burkholderia on the basis of 
DNA-DNA homology, 16s rRNA base sequences and various phenotypical 
characteristics (160). While the majority of these species are saprophytes or plant 
pathogens (56) three, B. cepacia, B. mallei and B. pseudomallei can cause potentially 
fatal disease in humans (6). 
1.1.2 Burkholderia mallei 
Glanders, a zoonotic disease primarily of solipeds, which can be traced back almost two 
thousand years (73), is occasionally transmitted to humans (48). At the turn of the 
twentieth century glanders was prevalent world-wide due to the extensive use of 
solipeds. The general decline in their use, however, together with the introduction of 
2 
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strict health enforcement procedures has led to a significant reduction in disease 
occurrence and it is now found primarily in Asia, Africa and the Middle East (5). 
B. mallei was first isolated in 1882 by Loefller and Schutz (19) and is a Gram-negative, 
non-motile, oxidase-positive, aerobic bacillus, 003-0.5 Jlm in width and 1-3 Jlm long and 
an obligate animal pathogen (51,160,220). Human susceptibility to it has not been 
studied in great detail although it has proven highly infectious in laboratory settings 
(29,73,95,193). 
1.1.3 Burkholderia pseudomal/ei 
First isolated by Whitmore and Krishnaswami (1912) from members of the population 
of Rangoon in Burma, exhibiting a glanders-like disease (225), B. pseudomallei has 
now been isolated from every continent on the globe (47). Confirmation of the 
taxonomic relatedness between B. mallei and B. pseudomallei vindicated Whitmore's 
original proposal of the specific epithet 'pseudomallei' (48) and later, Stanton and 
Fletcher (1921) suggested the term melioidosis, derived from the Greek JlllA.\~, 
meaning glanders or distemper of asses (48). B. pseudomallei is a Gram-negative, 
motile, facultative anaerobic bacillus usually less than 2 Jlm in length (96) that is 
responsible for a broad spectrum of illnesses observed in both humans and animals 
(48,96) and is a common cause of human pneumonia and fatal bacteraemias in endemic 
areas (35). 
1.1.3.1 Clinical manifestations 
The manifestations of melioidosis vary greatly from an asymptomatic state to chronic 
illness to acute overwhelming septicaemia (217,229). Its non-pathognomonic 
symptoms (123), together with the need for relatively sophisticated laboratory facilities 
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(50), often complicate diagnosis leading to the disease being mistaken for malaria, 
plague, pneumonia or miliary tuberculosis (96,123). 
The literature reports that the vast majority of infections appear to be sub-clinical (48), 
an observation supported by the fact that nearly 80% of children by the age of four 
years old (114) and up to 30% of adults (229) in endemic areas have antibodies to B. 
pseudomal/ei. Seroconversion during these mild and sub-clinical infections has been 
associated with a flu-like illness (7) although this is obviously difficult to confirm in 
every case. Since the description of the non-pathogenic B. thailandensis (192), which is 
antigenically cross reactive with B. pseudomal/ei (192) however, it is important to 
consider the possibility that the prevalence of seroconversion might in fact be due to B. 
thailandensis rather than B. pseudomal/ei, and that re-evaluation of this data may be 
appropriate. 
Latency periods as long as 62 years between B. pseudomal/ei infection and disease have 
been reported (123,136), with relapses usually occurring at times of stress, such as acute 
infections or trauma (48). The mechanisms of persistence still require further 
elucidation although localised foci of melioidosis in the lung, liver and spleen have been 
reported in animals and the utilisation of intracellular survival mechanisms is thought 
likely to play a part (229). In a 5-year study conducted in Sappasitprasong Hospital in 
north-eastern Thailand, Chaowagul et a/ (1993) (34) showed that nearly all suspected 
cases of recrudescence were actual melioidosis relapses and also estimated the rate to be 
approximately 15.3% (95% Cl, 10.5% - 22.3%) per year of follow-up. Difficulties in 
identifying individuals with latent infection however, means the exact numbers of 
seropositive people at risk from future relapse is unknown (48). 
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Only a small proportion of B. pseudomallei infections are sufficiently severe to come to 
medical attention. Sixty percent of these cases however, have positive blood cultures 
for B. pseudomallei and they usually present clinically as 'community-acquired sepsis 
syndrome' with a short history (1 day to 2 months) of pyrexia and rigors (35). The 
acute form of the disease can be divided into two groups, acute pulmonary, which is 
associated with pulmonary distress on presentation (22) and acute septicaemic forms. 
Approximately half of patients have evidence of a primary focus of infection (usually 
the lung, skin or subcutaneous tissues) and confusion, stupor, jaundice and diarrhoea 
may also be prominent features (48). Laboratory investigations usually reveal anaemia, 
neutrophilia, coagulopathy and renal and hepatic failure. Such patients deteriorate 
rapidly, developing widespread metastatic abscesses (particularly in the lungs, liver and 
spleen) and metabolic acidosis, which is accompanied by Kussmaul's breathing. The 
onset of septic shock is associated with mortality approaching 95% and the majority of 
patients die within 48 hours of hospital admission (35,48). Even with vigorous 
appropriate antibiotics and supportive therapy, mortality is still 40% or greater (229). 
If patients survive the acute phase of the disease, the manifestations of multiple septic 
foci, resulting from bacteraemic dissemination become prominent. The most common 
foci of infection are the lungs, liver, spleen, skin and soft tissues (48). The nervous 
system can also become involved in a syndrome known as neurological melioidosis, 
which is characterised by peripheral motor weakness, brain stem encephalitis, aseptic 
meningitis and respiratory failure (48). 
A sub-acute form of the disease also occurs, which has been described as a prolonged 
febrile illness (22). There is multiple abscess formation, although rarely on the brain, 
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and B. pseudomallei can be readily cultured from the blood, pus, urine and other bodily 
tissues and secretions in the later stages of disease (22,123). 
1.1.3.2 Epidemiology 
Endemic areas of melioidosis typically border 20° north and south of the equator 
although the incidence has been shown to be particularly high in Southeast Asia and 
northern Australia (35,47,48,49). The first indigenous case in Thailand was described 
in 1995 (47). It is now estimated that 20% of community acquired septicaemia and 
40% of deaths associated with bacterial sepsis in north-east Thailand can be attributed 
to B. pseudomallei (35), and 2000-5000 patients per year present with melioidosis (55). 
In northern Australia, melioidosis has been recognised as endemic since 1949 (83) 
although the exact route by which it was introduced remains unclear. The disease is 
also becoming increasingly prevalent in China, where it has been routinely isolated 
since 1975 (236), and in the Indian subcontinent, and recent surveys have shown that 
the organism is generally much more prevalent than previously believed (47). 
1.1.3.3 Reservoirs and transmission 
Stanton and Fletcher (1932) first identified melioidosis in animals, and concluded that 
the disease was a zoonosis with a reservoir in rodents. This theory was later disproved 
by French workers in French Indochina who observed a prevalence of disease 
occurrence following contact with muddy waters and that rats were rarely infected. 
Later they proved that B. pseudomallei was in fact an environmental saprophyte that 
could be readily isolated from soil and surface water in endemic areas (30). In 
particular the organism is associated with rice paddy fields (being readily isolated from 
68 - 78% of rice fields in Thailand) (48) and these habitats are thought to be the 
primary reservoirs from which susceptible hosts acquire infection (123). 
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Ecologically, B. pseudomallei is thought to persist in deeper clay layers during the dry 
season, rising to the surface after the annual rains and thus enhancing the potential for 
exposure of humans and animals (22). This supposition is one that fits with the marked 
seasonal variation seen with melioidosis whereby 75% of cases present during the rainy 
season in Thailand (20 I). It also fits with dramatic increases in incidence that 
frequently coincide with heavy monsoon rains in Australia (49), although as Dance 
(1998) (48) points out, this pattern implies that most cases are recently acquired. The 
incubation period of melioidosis (2 days to 62 years) (23,147,232) suggests that some 
other seasonal factor(s) might also precipitate relapses oflatent infections. Two studies 
have contradicted the seasonal variation theories by paradoxically finding a higher 
isolation rate of B. pseudomallei during the dry season than the rainy season (23,232), 
although technical reasons, such as the processing of larger samples during the dry 
season (232) or the dilution of B. pseudomallei during the rainy season (49) were noted 
as possible explanations for the findings. These studies suggest that the seasonal 
variation seen in melioidosis presentation may be due to increased exposure during rice 
planting or harvesting, rather than an actual increase in the number of organisms present 
in the soil (49). 
The most common route of infection for humans and animals is believed to be the 
inoculation or contamination of wounds or the mucine surfaces with soil or water 
(35,123). This tends to explain the prevalence of disease amongst rice farmers and their 
families who labour in the rice paddies without the benefits of protective clothing 
(35,123). However, specific episodes of exposure are only identified in approximately 
6% of cases in Thailand (201) and between 19% and 51% of cases in Australia (49). 
Aerosols have also been proposed as a possible route of infection, and were thought to 
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be a source of infection (aerosolised dust and fomites) for helicopter crews during the 
Vietnam War (96). While only two cases of person-to-person spread have been 
described (137), occasional iatrogenic infections from contaminated injections as well 
as laboratory-acquired infections have together led to the classification of B. 
pseudomallei as an Advisory Committee on Dangerous Pathogens (ACDP) category 3 
pathogen (1,116). There are currently no reports of disease transmission from animals 
to humans (122,123). 
1.2 Host-pathogen interactions 
For an invading pathogen to establish a successful infection it must first circumvent the 
plethora of innate (non-specific) and adaptive (specific) host defences that exist to 
combat the infective process. The role of the innate immune system is to prevent entry 
into the host or, if this occurs, to inhibit the establishment of infection. In addition 
however, the innate immune response is involved in the activation of adaptive 
immunity. This system provides a pathogen-specific defence mechanism aimed at 
stifling the infection process but also, importantly, establishing immunological memory 
such that future infections with the same pathogen are more efficiently combated (81). 
As discussed, the inoculation or contamination of wounds or the mucine membranes is 
likely the most common route of B. pseudomallei infection (35,123). Both the mucine 
and epithelial membranes however, are usually highly effective barriers to pathogen 
entry. Breech past the epithelial membranes is usually only possible through existing 
wounds or via vectors such as biting insects and the mucine membranes, while certainly 
more vulnerable to invasion, incorporate a number of effective barriers to infection such 
as mucus, cilia and their normal flora, which compete with invading pathogens for 
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adhesion sites and nutrients essential for the establishment of infection. Should breech 
occur, the resulting physiological response is inflammation. 
1.2.1 The innate immune response 
1.2.1.1 Acute inflammation 
The result of infection and/or tissue damage is an immediate, initially non-antigen-
specific, physiological response, which attempts to repair any damage and works in co-
ordination with the adaptive immune response to eliminate foreign bodies from the 
tissues. The release of inflammatory mediators, such as bradykinin and fibrinopeptides, 
from injured tissues causes localised vasodilation within minutes (13). The associated 
increase in blood volume reaching the affected area and increased vascular 
permeability, brought about by inflammatory mediators, results in localised oedema and 
an increase in leukocyte extravasation. Activation of the complement system produces 
anaphylotoxins (C3a, C4a and C5a), which augment the response inducing localised 
mast cell degranulation and the release of histamine (86,134). Within hours of the 
initiation of localised inflammation, neutrophils, which migrate along chemotactic 
gradients produced by the inflammatory response, begin adhering to the vascular 
endothelium and enter the tissue spaces. Macrophages are also recruited to the site of 
infection by the secretion of the macrophage inflammatory proteins (MIP-I a and MIP-
1 ~), and together with neutrophils form the first wave of defence against invading 
bacteria. Paradoxically however, macrophages also provide a niche within which B. 
pseudomallei, a facultative intracellular parasite, can grow and multiply (62,229). 
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1.2.1.2 Invasion 
The role of neutrophils and macrophages in terms of the innate immune response is to 
phagocytose and kill the bacteria in an attempt to prevent the establishment of infection 
and spread to other host tissues. However, entry to the intracellular environment is also 
an essential requirement for survival in the infective process for B. pseudomallei. For 
many intracellular bacteria, infection of neutrophils leads to killing of the pathogen due 
to the highly phagocytic nature and potent antibacterial activity of these cells 
(4,90,115). The significant contribution to reducing bacterial load early in infection 
provided by neutrophils has been demonstrated in experimental listeriosis, an acute 
disease characterised by extensive neutrophil infiltration at sites of listerial growth (38). 
Removal of the infiltrating neutrophils using monocIonal antibodies (mAb) exacerbated 
listeriosis in mAb treated mice (172). In addition to their highly potent antibacterial 
activity (90) the ability of neutrophils to sequester intracellular bacteria in intracellular 
niches (115). limiting bacterial spread, and their short life-span (4,90), providing 
insufficient time for an infection to become established, make neutrophils an unsuitable 
target. Macrophages and non-phagocytic cells however, provide an environment within 
which B. pseudomallei can survive and proliferate for prolonged periods (111,162). It 
is this ability to persist in the intracellular environment, which is thought to be 
responsible for the pathogenesis of B. pseudomallei infection and its recrudescence (44) 
and may also provide some explanation of why melioidosis is refractory to antibiotic 
therapy (198), although the antibiotic resistance of B. pseudo mallei has also been 
demonstrated in vitro (222). 
Entry into the intracellular environment, whether due to invasion or phagocytosis, is 
ultimately a function of the host cell defence mechanisms (115), although in terms of 
facultative intracellular pathogens such as B. pseudomallei it is often induced through 
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molecules that first mediate adhesion to the host cell. Adhesion induces uptake through 
host cell receptor signalling in a process that has been termed the 'zipper mechanism' 
(40,202). While a specific receptor for this mechanism in terms of B. pseudomallei 
infection has not yet been identified, a cluster of B. pseudomallei genes with homology 
to the type III protein secretion systems of Salmonella typhimurium and Shigella 
jlexneri has been identified (10,164,199). These secretion systems have been likened to 
a molecular syringe (198) whereby bacterial proteins are injected directly into the 
cytosol or plasma membrane of the target, which then interact with host cell receptors 
and proteins and bring about the uptake of the bacterium. These systems have been 
demonstrated to induce bacterial uptake in a variety of non-phagocytic cells for both 
Salmonella and Shigella. The Burkholderia homologues identified (termed the 
Burkholderia secretion apparatus, Bsa) have also been shown to facilitate bacterial 
invasion of He La cells (reviewed in (198». 
Uptake into the intracellular environment of the professional phagocyte should, in terms 
of a successful immune response, lead to the formation of a phagolysosome. The 
purpose of the phagolysosome and other associated endocytic vesicles is to effect 
bacterial killing through a number of mechanisms, such as the production of reactive 
oxygen and nitrogen intermediates (ROI and RN I), defensins (184) and lysosomal 
enzymes (115) and also provide immunogenic proteins to enable the establishment of 
adaptive immunity. Most intracellular bacteria however, interfere with the maturation 
of the phagosome and alter its composition to facilitate and support their own survival 
(115). 
Transmission electron microscopy has indicated that B. pseudomallei can escape from 
endocytic vesicles as early as fifteen minutes after internalisation (89). It has been 
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hypothesised that the Bsa is likely to play a role in this, due to observations that 
dependence on a type III secretion system is a feature of endosomal escape in Shigella 
infection. It has also been demonstrated that B. pseudomallei mutants lacking putative 
components of the Bsa are confined to endosomes with intact membranes in 1774.2 
macrophages (199). Furthermore the mutant bacteria were found to co-localise with 
lysosome-associated membrane glycoprotein-I (LAMP-I), which is a marker of late 
endosomes, whereas the wild type bacteria did not, suggesting a role for the Bsa in 
endosomal escape (199). 
Following escape from the endosomal compartment, B. pseudoma/lei attempts to 
establish a successful infection while the host attempts to stifle it. An important factor 
in the ensuing battle is intracellular iron, which is required by the bacteria and also 
required for the production of ROI and RNI by the host. To improve iron supply the 
host utilises transferrin and lactroferrin molecules, which bind iron in the extracellular 
environment and allow uptake into the cell via transferrin receptors. Iron is then 
released from the transferrin in the reducing conditions of the early phagosome and 
transported to the cytosol. Bacteria also utilise a number of mechanisms such as 
siderophores, transferrin-binding proteins, haem-like proteins and adenosine 
triphosphate (ATP)-Binding Cassette (ABC) transporters (115) to scavenge iron from 
the invaded cell for the purposes of infection. The importance of iron in B. 
pseudomallei infection is highlighted by work undertaken by Bancroft and colleagues, 
who also demonstrated an obligatory role for interferon-gamma (IFN-y) in host survival 
in the murine model of B. pseudomallei infection (177). When infected, mice 
developed an acute lethal infection unless a rapid IFN-y response was mounted within 
the first 24 hours. Following such a response, a chronic infection was induced that 
lasted between 2 and 16 months before lethality (177). IFN -y activated macrophages 
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down-modulate transferrin receptor expression, resulting in a significant reduction in 
iron availability within the phagosome and thus ultimately the cell (115). Thus it could 
be hypothesised that reduced iron, in addition to heightened killing activity, might be an 
important infection limiting control. 
Once the host's defensive mechanisms have been stifled a successful infection can then 
be established. B. pseudoma//ei is then able to induce the formation of actin-based 
membrane protrusions (199), an ability shared by other intracellular bacteria such as 
Shigella, Listeria and Rickettsia spp., that allows the formation of conduits between 
cells, enabling the spread of infection. In addition to actin-based motility, B. 
pseudomallei is also capable of inducing cell fusion, an attribute unique to this bacterial 
pathogen (116). The mechanisms behind the formation of multinucleate giant cells 
(MNGC) during B. pseudoma//ei infection are yet to be fully elucidated. However the 
formation of MNGC has been observed both in vitro (116) and in human melioidosis 
patients (228) suggesting it is likely to play a role in the protection of B. pseudomallei 
from the adaptive immune response and to allow recrudescence (115). 
1.2.2 The adaptive immune response 
In the vast majority of cases an innate immune response alone is insufficient to contain 
proliferation of the invading pathogen. Thus an adaptive, pathogen-specific, response 
must be established to aid clearance and protect against future infections with the same 
pathogen. Central to the establishment of adaptive immunity are dendritic cells (DC). 
1.2.2.1 Dendritic cells 
Dendritic cells (DC) are a rare, heterogeneous population that reside in most peripheral 
tissues and organs representing approximately 1-2% of the total cell population 
13 
Chapter 1 -lntroduction 
(81,130). They belong to a group of cells called antigen-presenting cells (APCs) 
defined by their ability to express surface major histocompatibility complex (MHC) and 
deliver a co-stimulatory signal via CD 80 and CD 86 (the B7 molecules B7-1 and B7-2 
respectively) to activate naIve CD 4+ and CD 8+ T cells. A variety of cells can function 
as APCs following induction to express MHC and/or co-stimulatory molecules, 
although these cells usually only function in this capacity during sustained 
inflammation and for short periods (81). Of the 'professional' APCs, DC are by far the 
most potent and the only cells to constitutively express high levels of MHC, CD 80 and 
CD 86. They are also the only cells capable of efficiently activating naIve T cells 
without further stimulation from other immune cells (12,45,143,181). 
1.2.2.1.1 Haematopoietic development 
The development of DC has been described along a number of different pathways that 
encompass both myeloid and lymphoid lineages (72,157,174). In humans three 
generalised types of DC have been described: myeloid, plasmacytoid (170) and 
lymphoid DC. In vitro the development of myeloid DC can be achieved from CD 34+ 
progenitor cells under the influence of the growth stimulating cytokine granulocyte 
macrophage-colony stimulating factor (GM-CSF) and the inflammatory cytokine 
tumour necrosis factor-alpha (TNF-a) (27,126,157). Under this environment CD 34+ 
bone marrow progenitors differentiate into CD 14-, CD 11c+, CD la+ cells that resemble 
epidermal DC (Langerhans cells) and contain the characteristic Birbeck granules 
(27,157). The addition of transforming growth factor (TGF)-P 1 to the culture again 
results in a DC with a CD 14-, CD 11 c +, CD 1 a + phenotype, but these cells lack Birbeck 
granules and are known as dermal or interstitial DC (79). In addition, the development 
of an intermediate DC stage from CD 34+ progenitors has been demonstrated under the 
influence of interlukin (IL) -1 P, IL-3, IL-6, erythropoietin (EPO) and stem cell factor 
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(SCF) (178,180). This cytokine cocktail produces a CD 14+ CD 1 a· cell that has bi-
potential for both DC and monocytes and also represents the precursor to plasmacytoid 
DC (POC). The differentiation of POC can thus be induced from these cells under the 
influence of GM-CSF and IL-4, or directly from progenitor cells in the presence of fms-
like tyrosine kinase receptor ligand (Flt-3L). PDC belong to a group of cells designated 
type I interferon (IFN)-producing cells owing to their capacity to secrete high 
concentrations of type I IFN after viral challenge (126,157,170,213). They have been 
described in the peripheral blood and lymph nodes of patients with infectious diseases 
and recent work suggests their primary role is likely to be in antimicrobial defence (37). 
In addition to these myeloid related pathways, a potential link between DC development 
and lymphocytes has also been demonstrated (74). A subset of CD 34+, CD 38+, Lin-, 
CD 10+ progenitor cells has been identified in human bone marrow that are capable of 
giving rise to T, B, Natural Killer and DC but not myeloid cells upon exposure to 
multiple cytokines (74,181). Lymphoid DC have also been shown to develop from CD 
34+, CO 38dim thymic precursors under the influence of IL-Ia, IL-3, IL-7, SCF and 
GM-CSF (157,181) and from CD 19+ precursors in the presence of IL-lj3, IL-3, IL-7, 
SCF, Flt-3L and TNF-a in the presence of serum (74,157,181,187). A number of 
functions have been proposed for lymphoid DC although their capacity for inducing 
apoptosis and involvement in the elimination of self-reacting T cells has lead to the 
suggestion that their role is primarily one of regulation rather than stimulating effector 
funGtions (181). 
In the mouse, DC can be divided into three main subclasses on the basis of their 
phenotype. While all murine DC express the CD 11 c intergrin they can be 
distinguished by their expression of CD 8a, CD 4, CD 45R (B220) and Grl. CD 8a+ 
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DC, which differentiate along the myeloid lineage (214) (denoted by the expression of 
the myeloid marker CD lIb), have been described in the thymic cortex and T cell areas 
of the secondary lymphoid organs (Reviewed in (188». There is currently no human 
counterpart to CD 8a + DC that has been identified and this also appears to be the only 
group of DC specialised in the capture of apoptotic bodies from B cells and tumour 
cells (104). CD 8a- DC are also of myeloid lineage, differentiating from the same 
myeloid precursor as CD 8a + DC, and expressing CD 11 b. This population can be 
further divided into CD 4+ and CD 4-, both of which are found to reside in the marginal 
sinus of the spleen, subepithelial dome of Peyer's patches and in the peripheral tissues. 
The differentiation of DC from monocytes in mice has also been demonstrated (165) 
and recently a CD llc+ population of DC also positive for CD 45R and OrI but with 
only low expression of CD 11 b has been described in the mouse. This population of 
DC resembles human PDC in their capacity to secrete type I IFN following viral 
stimulation (37) and are thus now considered the murine equivalent ofPDC. 
In both humans and mice different DC subsets appear to have specialised functions 
focused on driving effector and/or regulatory T -cell differentiation (170). A 
considerable degree of elucidation is still required however, before the mechanisms 
underlying the plasticity exhibited by DC can be detennined. Central to their role in the 
control of the adaptive immune response however, is their ability to recognise and 
differentiate the array of pathogens encountered by the immune system. 
1.2.2.1.2 Pathogen recognition 
Despite the antigen specificity ofB and T cells they lack the ability to direct and control 
immune responses. This complex task is one carried out by DC via genn line-encoded 
pattern recognition receptors (PRRs) (105,140). Although tremendously diverse, 
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microorganisms possess common structural features such as, lipopolysaccharide (LPS), 
peptidoglycan, lipoteichoic acid, lipoarabinomannan, unmethylated DNA and bacterial 
lipoproteins, which are known as pathogen-associated molecular patterns (PAMPs). The 
role of PRRs in the detection of PAMPs was first hypothesised by Janeway (1992) 
(105) following the discovery of the gene for the Drosophila Toll protein that is 
involved in the secretion of the anti-fungal peptide drosomycin in response to microbial 
invasion (reviewed in (113». In 1997, the first human homologue of Toll was 
described and later designated Toll-like receptor (TLR) 4, due to the identification of 
additional murine and human TLR proteins since the discovery of the Toll gene in the 
early 1980s. Mammalian TLR proteins have since been shown to represent a conserved 
family of innate immune recognition receptors that are found in mammals, insects and 
plants (139). These receptors are coupled to signalling pathways that enable the 
activation of immune cells in response to infectious agents in a manner similar to the 
PRRs envisioned by Janeway (1992) (105). 
Research into the functions of PRRs and their ability to recognise PAMPs demonstrated 
that they offered cells of the innate immune system, such as DC, a means of 
discriminating between different stimuli. For example, LPS signals through TLR 4, 
peptidoglycans through TLR 2, CpG bacterial DNA through TLR 7 and 9 and bacterial 
flagellin signals through TLR 5. Research has also shown that many PAMPs signal 
through more than one TLR and it has been suggested that it is these combinations of 
TLR activation that lead to the appropriate expression of cytokines to drive a specific 
immune response (2,98,139,163,223). 
DC have been demonstrated to be the principle cell involved in antigen presentation to 
naIve T cells (43,85,233) and thus to fulfil this function and initiate adaptive immunity, 
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DC must engage and activate other immune cells to establish an effective response. 
Once endocytosed the invading pathogen is digested and processed by the DC to form 
antigenic peptides. These peptides are then presented, in the context of MHC class I 
and 11 molecules, to naIve T cells allow other immune system cells to recognise the 
invading pathogens and mount a pathogen-specific response (102,145). In addition, the 
recognition of pathogen-specific immunogenic peptides also enables the production of 
memory T cells and immunological memory such that future infections can be 
combated with greater speed and efficacy (39,57,58,64). 
1.2.2.1.3 Antigen uptake 
Under physiological conditions DC reside in an immature or un-activated state during 
which they are primed for the uptake and processing of anti genic peptides. In this form 
DC express relatively low levels of MHC class 11 and the co-stimulatory molecules CD 
80 and CD 86, making them inefficient T cell activators (12,84). They do however, 
express a plethora of markers involved in the uptake of anti genic peptides and microbes. 
Immature DC are located at the major portals of microbial entry, such as the skin and 
mucine membranes, which allows them to perform a sentinel-like function, 
continuously sampling their external environment via phagocytosis and 
macropinocytosis (170). 
Both phagocytosis and macropinocytosis are actin dependent mechanisms the latter 
requiring membrane ruffling and resulting in the formation of large intracellular 
vacuoles (84). While phagocytosis is receptor-mediated, macropinocytosis is a 
cytoskeletal dependent type of fluid-phase endocytosis, which is constitutive in 
immature DC and can be transientIy induced in macrophages (176). Macropinocytosis 
represents a major antigen uptake mechanism in immature DC allowing them to rapidly 
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and non-specifically sample large amounts of the surrounding extracellular fluid. 
Phagocytosis, in contrast, involves the engagement of specialised receptors, such as C-
type lectins like the macrophage-mannose receptor (MMR) (175) or CD 205 (110), or 
the use of specialised regions of the plasma membrane termed clathrin-coated pits 
(191,195). This process does not require membrane ruffling and is initiated by a signal 
in the cytoplasmic tail of an endocytic receptor, which leads to invagination of the 
membrane and macromolecule internalisation. Thus for both receptor-mediated 
endocytosis and phagocytosis the first step is the contact between an invading microbe 
and the DC. During this event, many parallel signalling pathways are simultaneously 
activated defining the cellular response and regulating internalisation (218). A large 
number of endocytic receptors are selectively expressed on subpopulations of immature 
DC including: Fcy-receptors, C-type lectins, complement receptors, scavenger 
receptors, lectins, heat shock proteins and integrins such as fibronectin and vitronectin 
(84,218). Of these, some are involved in transmitting intracellular signals to trigger 
antigen uptake, while others are primarily involved in binding or increasing the 
efficiency of internalisation. This latter group of receptors including, chemokine 
receptor (CCR) 5 (156) and dendritic cell-specific- ICAM 3-grabbing nonintergrin (DC-
SIGN) (78), also serves as a target for pathogens, being exploited to facilitate infection 
(221). 
The production of pro inflammatory signals and activation of antimicrobial mechanisms 
usually accompanies microbe internalisation. While certain phagocytic receptors, such 
as Fc-receptors (166), trigger inflammatory responses directly, others such as 
complement receptors do not (231,235). In these cases the activation of inflammatory 
responses during phagocytosis is mediated by additional receptors (not themselves 
phagocytic) such as TLR's (218). This inflammatory response alone however, is 
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insufficient to mount a defence against microbial invasion. The ingested pathogen must 
be processed to form antigenic peptides, which can be used to activate the adaptive 
immune response. 
1.2.2.1.4 Antigen processing and presentation 
As previously described, immature DC are poor activators of naive T cells. Thus 
pathogen recognition serves two major purposes. First, it triggers effector cells of the 
innate immune system such as macrophages and neutrophils, which represent an 
immediate defence at sites of pathogen entry. Second, it spurs DC into an integrated 
developmental program known as maturation, which transforms them into efficient T 
cell stimulators (84) allowing the initiation of an adaptive immune response. 
The precise coordination between the phenotypical, morphological and functional 
modifications induced during maturation has yet to be completely elucidated (84). 
Current opinion is that after an encounter with a pathogen, DC leave the peripheral 
tissues in an intermediate state of maturation and migrate to the draining lymph nodes 
where they become fully mature under the control of antigen specific T cells. During 
this migration, previously internalised microbes and antigens are degraded 
intracellularly and loaded onto MHC molecules for future presentation to nai·ve T cells 
(reviewed in (84». The DC invokes a strict compartmentalisation on the biogenesis of 
MHC class I and class 11 molecules meaning that while both exogenous and endogenous 
antigens are loaded onto MHC class 11 molecules, only selected endogenous antigens 
are loaded onto MHC class I molecules (16). 
The loading of peptides from recently processed pathogens onto MBC class 11 
molecules occurs via the endocytic pathway. Shortly after their synthesis in the 
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endoplasmic reticulum (ER), three aJP MHC· class 11 dimers associate to a trim er of 
invariant (Ii) chains forming a nonameric molecule (41). Under the influence of 
transport signals present in the cytoplasmic region of the Ii chain the nonamers then 
pass through the Golgi apparatus where they are packaged before transport to the 
endocytic pathway (41). Here they fuse with endosomes and lysosomes, encountering 
an acidic, protease-rich environment, which leads to the degradation of the Ii chain 
leaving only a class-II-associated Ii peptide (CLIP) in the peptide binding groove 
(118,212). Competency to bind anti genic peptides then develops under the control of 
two nonpolymorphic MHC class 11 molecules HLA-DM and HLA-DO in humans and 
H2-M and H2-0 in mice, which catalyse the exchange of CLIP for antigenic peptides 
(118). In parallel to the generation of competent MHC class 11 molecules, the endocytic 
pathway also produces antigenic peptides, called epitopes through the proteolysis of 
ingested pathogen-associated proteins. These bind competent MHC class 11 molecules 
forming a MHC class II-epitope complex that is transported to the plasma membrane 
(159,224). 
In their immature form DC exert a tight regulation on the amount of MHC class 11-
epitope complexes that are expressed on the cell surface through several intracellular 
mechanisms. First, antigen degradation in immature DC is very inefficient, due to the 
low efficiency of several of the proteases involved in the endocytic pathway (66). This 
means that internalised antigen can remain intact for several days in the lysosomal 
compartments, restricting the availability of antigenic peptides for MHC class 11 loading 
(101). Second, low protease activity (specifically cathepsin S) means that some MHC 
class 11 haplotypes with a strong affinity for Ii remain associated with a partially 
degraded form of Ii, called lip 10, which blocks access to the peptide binding groove 
(158). Even in cases where lip 10 is degraded in the lysosomal compartment, MHC 
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class II-epitope complexes that reach the cell surface are rapidly internalised again 
either to be associated with new epitopes in recycling endosomes or to be directed to 
lysosomes where they are degraded (28). In either case this results in a very short-term 
presentation of MHC class II-epitope complexes on the immature DC surface that is 
insufficient to stimulate naiVe T cells into an effector response. 
Maturation signals encountered by DC induce the coordinated modification of all 
aspects of MHC class II-epitope complex formation and transport (84). A transient 
increase in MHC class 11 synthesis occurs (28) accompanied by increased cathepsin S 
and other protease activity (66) resulting in the increased availability of MHC class 11 
molecules and antigenic peptides with which to form complexes. Once formed, the 
MHC class II-epitope complexes are rapidly transported to endosomal vesicles where 
they co-localise with the co-stimulatory molecules CD 80 and CD 86 and MHC class I 
molecules. The result is a cluster of molecules involved in T cell stimulation that are 
transported to the cell surface (216). In order to restrict the specificity of T cell 
stimulation to those antigens encountered in the periphery, maturation is also 
accompanied by a significant down-modulation of endocytic activity. Most antigen 
receptors, including Fc receptors, MMR, CD 205 and receptors for heat shock proteins 
and apoptotic bodies are significantly down-regulated representing the first level of 
control on antigen uptake (75). The only exceptions to this are clathrin-coated pits and 
vesicles involved in receptor-mediated endocytosis, which are not down regulated. 
Secondly, the overall levels of phagocytosis and macropinocytosis are reduced via the 
GTPase, Cdc42, which plays a central role in the blocking of macropinocytosis and 
phagocytosis (212). Stabilisation ofMHC class II-epitope complexes on the surface is 
achieved through a significant reduction in the transport of internalised MHC class 11 
molecules to Iysosomes for degradation. Later, there is a further focusing of the T cell 
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response to only those antigens encountered in the periphery. This occurs through 
down regulation of MHC class 11 synthesis and the fact that the association of epitopes 
with newly synthesised MHC class 11 molecules becomes very inefficient (84). 
MHC class I presentation to CD 8+ T cells is generally limited to those proteins that are 
actively synthesised within the cell. Epitopes from endogenous antigens are generated 
in the cytosol by proteosome degradation and then transported to the ER by proteins 
present in the membrane of rough ER called transporters associated with antigen 
processing (TAP). Once transported, epitopes are then loaded onto MHC class I 
molecules, under the control of a loading complex composed of ER resident chaperone 
proteins such as tapasin, calnexin and calreticulin (42), ready for presentation. Once 
formed, MHC class I-epitope complexes are rapidly transported through the Golgi and 
on to the plasma membrane (84). The control exerted on MHC class I biogenesis and 
loading by the DC varies to that of MHC class 11. Studies have shown that the 
expression ofMHC class I-epitope complexes is up-regulated upon the induction of DC 
maturation (171) although to a lesser extent than MHC class 11 (28). In contrast 
however, MHC class I complexes are still efficiently synthesised and transported to the 
plasma membrane in mature DC indicating a functional difference in the regulation of 
antigen presentation to CD 4+ and CD 8+ T cells (171). While this pathway is suitable 
for the presentation of viral protein by infected cells and self-proteins, in terms of 
bacterial, including B. pseudomallei, infection cytotoxic immune responses need to be 
initiated against exogenous antigens not synthesised by the DC. 
In most cells the cytosol and ER do not exchange material with the endocytic 
compartments (80), which means that epitopes from exogenous antigens do not have 
access to MHC class I molecules. The process of presenting exogenous peptides on 
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class I molecules was first described by Bevan 1976 (16), who demonstrated that 
priming of cytotoxic T lymphocyte (CTL) responses in vivo could occur after 
presentation of exogenous antigens by MHC class I molecules, a process he called 
cross-priming (16). More recent studies have demonstrated the ability of DC to carry 
out cross-priming of antigens from virally infected cells (189), tumour cells (97), 
apoptotic and necrotic cells (3,237). Both macropinocytosis (148) and phagocytosis 
(186) are thought to be major routes of antigen uptake for the cross-presentation of 
exogenous antigens and dendritic cells are considered especially efficient for generating 
CTL responses via the cross-presentation pathways (237). 
Thus DC act as coordinator of the immune response aiding innate immunity and also 
bridging the gap between innate and adaptive immunity as well as providing the driving 
force behind the type of adaptive immune response generated. The ultimate effect of 
DC maturation is to produce antigenic epitopes from foreign antigens and transform the 
cell into an efficient APC capable of stimulating naive T cells to proliferate. 
1.2.2.2 T cell stimulation by dendritic cells 
Following their exit from the thymus, all up CD 4+ T cells have a naIve phenotype and 
require an activation stimulus before they can differentiate into effector cells capable of 
mediating either type 1 (cellular) or type 2 (humoral) effector responses. The 
phenotypic similarities of effector T cells mediating type 1 (Th 1) and type 2 (Th2) 
responses means that reliably distinguishing between the two subgroups often relies on 
an assessment of their functional characteristics (146). Such differentiation is based on 
the profile of cytokines produced by each subset following activation. Th 1 cells can be 
defined by their production of cytokines such as interferon (lFN)-y and tumour necrosis 
factor (TNF)-P while Th2 cells produce interlukin {IL)-4, IL-5, IL-6, IL-to and IL-13 
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(146). A third subset of CD 4+ T cells, ThO cells, producing a mixed cytokine profile 
(39,70,151) has also been described. The use of in situ mRNA hybridisation (allowing 
the detection of cytokines from individual cells) (26) and intracellular protein staining 
(150), however, has suggested that the ThO subset is likely a m ixed population of Th I 
and Th2 cells (39) rather than a distinct population. 
The activation and clonal expansion of CD 4+ T cells is mediated by the engagement of 
surface bound receptors on the T cell. The T cell receptor (TCR) is a membrane bound 
protein heterodimer composed of either a and p or y and 8 chains. Unlike the B cell 
receptor, which directly recognises antigenic peptides derived from invading pathogens, 
the TCR must have antigenic peptides presented to it in association with molecules of 
the major histocompatibility complex (MHC) family on the surface of antigen 
presenting cells (120). This recognition of MHC associated antigen by the TCR is the 
central event in T cell activation. The TCR itself consists of a mostly extracellular 
heterodimeric ligand binding unit, and an intracellular signalling unit. The signalling 
unit consists of three different polypeptide chains collectively known as CD 3, which 
associate with the TCR at the T cell membrane and are involved in mediating signal 
transduction (120). The signalling process is initiated by the engagement of the 
peptide-MHC complex with the TCR, which causes cross-linking and allows the 
association of the protein tyrosine kinase, Fyn, with the cytoplasmic tail of the TCR-CD 
3 complex (91). This event also causes the translocation of the accessory molecules CD 
4 (in c1ass-II restricted T cells) or CD 8 (in c1ass-I restricted T cells), which bring with 
them the Lck protein tyrosine kinase, that is bound to their intracellular domains, 
allowing association with the cytoplasmic tails of the TCR. Once associated, the 
phosphorylation of the immune tyrosine-based activation motif (IT AM) occurs under 
the control of the leukocyte common antigen CD 45, which is a transmembrane tyrosine 
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phosphatase that removes phosphates from the inhibitory sites of Fyn and Lck. This in 
turn leads to the activation of ZAP-70 (91) that initiates a number of signalling 
pathways ultimately leading to the activation (by dephosphorylation) of the T -cell-
specific nuclear factor, NF-AT, together with NF-KB. These nuclear factors translocate 
to the nucleus and initiate transcription of the various genes required for activation and 
clonal expansion (120). 
Naive T cells however, also require a second signal from the co-stimulatory molecule 
CD 28, which is activated by CD 80 and CD 86 (12). Activation of this molecule 
initiates a signalling cascade that results in the activation of several other nuclear factors 
that induce gene transcription strengthening the activation of the T cell (18,120). 
Approximately 48 hours after activation, the naive T cell enlarges into a blast cell and 
begins a phase of rapid cell division, 2-3 times per day for 4-5 days, which generates a 
large number of clone progeny cells. These cells then further differentiate into effector 
T cells, which carry out required immunological functions such as B cell help (CD 4+ T 
cells) or cytotoxic killing activity (CD 8+ cytotoxic T cells), or memory T cells (121). 
Memory T cells are longer lived than effector cells and can be derived from both naive 
and effector cells following an encounter with antigen (46,121). Once differentiated, 
memory cells reside in the Go phase of the cell cycle but possess a lower activation 
threshold enabling a more rapid activation upon subsequent antigen exposure (121). 
Aside from TCR engagement, the outcome of T cell stimulation is influenced by a 
variety of other factors such as, the subset of DC providing T cell stimulation and the 
maturation-inducing signals encountered by the DC. Previous work has demonstrated 
that monocyte-derived human DC matured by CD 40 ligand, IFN-y, LPS, CpG's or 
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double-stranded RNA produce high levels of IL-12 and thus a type 1 response. In 
contrast however, stimulation with prostaglandin E2 does not lead to IL-12 secretion 
and thus causes a type 2 response (reviewed in (84». The ability to alter the effector 
immune response in this way is a concept called polarised maturation. CD 4+ T cells 
can be skewed to produce a Tb 1 or Tb2 response through the use of maturation signals 
or co-stimulatory molecules that favour one response over the other. A similar effect is 
seen from pathogen-derived signals, which play a critical role in the regulation of 
cytokine secretion by DC. In the yeast stage, Candida albicans induces IL-12 
production and a type 1 response; while at the hyphae stage it has been demonstrated to 
induce IL-4 secretion favouring a type 2 response (84). Tissue specific environmental 
conditions also play a role as DC from different tissues have been shown to induce 
different responses to the same stimuli (103). Equally important in determining the 
outcome of T cell contact is the duration of DC stimulation, since over-stimulated DC 
have been shown to prime mostly Th2 and non-polarised, or central memory T cells 
expressing chemokine receptor (CCR) 7 (206). 
1.2.3 Humoral immunity 
1.2.3.1 B cell stimulation 
B cell development begins in the bone marrow as lymphoid stem cells differentiate into 
progenitor B cells (127,135,173). Maturation ofthe B cell from this early stage requires 
not only several local environmental factors such as IL-7 (14,54), but also the 
rearrangement of the immunoglobulin (lg) (the B cell receptor) DNA (173). This 
rearrangement results in the production of a receptor with a unique antigenic specificity 
and also enables the B cell population to produce receptors to antigens never previously 
encountered (127,173). As the B cell continues to mature IgM and IgD are expressed 
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on the cell surface (127) and the population then proceeds through a process of clonal 
deletion such that B cell receptors reactive against host antigens are removed from the 
host's repertoire (141,142) before export from the bone marrow. 
Once mature, B cells circulate in the blood for a few weeks until they undergo apoptosis 
(141). Activation within this time is purely a function of encounter with antigen and the 
result is dependent on whether the antigen is thymus dependent (TD) or thymus 
independent (TI). An encounter with TI antigens, such as LPS or bacterial flagellin, 
which does not necessarily lead to an antigen specific response, is dominated by the 
secretion ofIgM and does not lead to the production of memory cells (138). 
In contrast to TI antigen activation of B cells, TD antigen activation is dependent on Th 
cells (94). After binding of antigen by monoclonal Ig on the surface of the B cell, the 
antigen is internalised and processed through the endocytic pathway into anti genic 
peptides. Simultaneously, the surface expression of MHC class 11 and the co-
stimulatory molecules CD 80 and CD 86 is up regulated, enhancing the B cells antigen 
presentation capability (94,141). Antigenic peptides are then loaded onto MHC class 11 
molecules and transported to the cell surface to enable binding to and activation of Th 
cells. This event causes the secretion of cytokines such as IL-2, IL-4 and IL-5 from the 
Th cell which bind the B cell leading to clonal expansion and differentiation into 
antibody secreting plasma cells and memory B cells (94,138). 
1.2.3.2 Immunoglobulin isotype and function 
Antibodies perform two important activities: the specific binding to an antigen; and the 
participation in various biological effector functions, which is determined by the isotype 
of the heavy-chain constant domain. There are five main classes of Ig in mammals; 
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IgM, IgG, IgA, IgD and IgE, each of which confers class specific structural and 
functional properties. 
IgM mediates opsonisation, which involves the coating of an invading pathogen with 
antigen specific antibody. Phagocytic cells, recruited to the site of infection, then bind 
to the opsonising antibody via Fc receptors (specific for the Fc portion of Ig) expressed 
on the phagocytic cell surface, an event that leads to phagocytosis and destruction of the 
invading pathogen. IgM is also involved in the activation of the complement pathway, 
which culminates in the formation of the membrane attack complex that perforates the 
membrane of Gram positive bacteria and host infected cells causing lysis and death. 
IgG is divided into 4 subclasses, designated 1 to 4 in humans and 1, 2a, 2b and 3 in 
mice, each of which has a different biological function. In humans, IgG 1 and 3 are the 
predominant activators of complement and the strongest opsonising isotypes although 
IgG2 and 4 are also opsonising (81). In mice the IgG2a and 2b sUbtypes are 
predominantly involved in the activation of complement and all isotypes are involved in 
opsonisation (106). 
1.2.3.3 Antibody dependent cellular cytotoxicity 
In addition to these mechanisms of antibody-assisted killing, a third mechanism, 
antibody dependent cellular cytotoxicity (ADCC) utilises antibody to facilitate the 
killing of infected host cells (63,106). JgG secreted during an infection binds to 
infected host cells through recognition of foreign antigen displayed on the cell surface. 
This enables non-specific cytotoxic cells, such as natural killer cells, monocytes, 
macrophages, neutrophils and eosinophils (63), and some evidence suggests, 
lymphocytes (129), to bind to the target cell, via the Fe region of the antibody, and 
mediate killing in the absence of complement. Evidence suggests that target cell killing 
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is mediated through the release of lytic enzymes, perforin, TNF and granzymes 
(9,15,81) the cumulative effect of which causes lysis and cell death, preventing the 
spread of infection. 
1.2.4 Treatment of Burkholderia pseudomal/ei infection 
B. pseudomallei is intrinsically resistant to many antibiotics including aminoglycosides 
and early j3-lactams (48). A complete lack of response to both penicillin and 
gentamicin, a commonly used combination for the treatment of septicaemia in the 
tropics, is characteristic of melioidosis (35,109). Despite this, j3-lactam drugs such as 
ceftazidime, co-amoxiclav and imipenem have halved the mortality of melioidosis since 
the mid 1980's (50). A number of studies have also demonstrated the susceptibility of 
B. pseudomallei to a number of other antibiotics including some third generation 
cephalosporins (such as cefotaxime and ceftriaxone), ureidopenicillians, tetracyclins, 
trimethoprim-sulphamethoxazole and fluoroquinolones (reviewed in (33». Treatment 
is usually given in two phases, an acute parenteral phase that lasts between 10 - 14 days 
(50) and 4 weeks (109), followed by an oral eradication phase lasting 3 to 6 months 
(50,109). Despite many advances in melioidosis treatment, acute mortality, especially 
in Thailand, still remains high (50). 
1.2.4.1 Current Burkholderia vaccines 
Increasing recognition of melioidosis as a significant cause of morbidity and mortality 
together with complications in treatment has led to a number of studies investigating 
immunoprophylaxis for the disease (229). While presently no vaccine exists to protect 
against melioidosis, a number of approaches have shown promise, including 
immunoglobulin therapy (21,24) and conjugate vaccines (reviewed in (22». Other 
approaches include the use of recombinant vaccines based both on B. pseudo mallei (8) 
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and other bacteria (56), and attenuated mutants of B. pseudomallei, which have been 
used with some success (8). 
1.2.5 Pathogenesis of Burkholderia pseudomal/ei disease 
The literature suggests that the vast majority of B. pseudomallei infections are sub-
clinical (7,48,114,229), although this literature does not take into account the degree of 
seroconversion caused by B. thailandensis (20). If, however this is in fact the case, then 
it suggests that the immune response to B. pseudomallei in immunocompetent 
individuals is usually sufficient to suppress the emergence of disease. However, in a 
minority of cases of primary infection or during recurrence, an acute, septic infection 
results, which overwhelms the host immune response and death usually ensues 
(126,229). 
The exact reasons for such a difference in disease presentation still require elucidation. 
There is evidence that host resistance is strongly influenced by the cell-mediated 
response. This was first suggested by studies showing an impaired cellular immune 
state in melioidosis (207), and later through the demonstration that the use of the 
immunopotentiating agent levamisole as a treatment for melioidosis patients, 
substantially improved their recovery rate (208). More recent studies have 
demonstrated a key role for IFN-y in controlling melioidosis in the mouse model (177), 
and that natural killer cells and CD 8+ T cells, activated by a cytokine-dependent 
bystander mechanism, are the most important sources of the rapid production of IFN-y 
(124). In contrast, despite the apparent frequency of seroconversion in melioidosis 
endemic areas, evidence of a role for the humoral immune response in protection is 
often contradictory. A number of studies into the pathogenesis of and immunity to 
melioidosis have found no correlation between circulating antibody and protection 
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against disease (7,114,229). In contrast however, the success of passive immunity 
studies utilising both immune sera (24) and monoclonal antibodies (112) has also been 
demonstrated. 
These combined data demonstrate that significant further work is required to properly 
elucidate the immune mechanisms required for protection against melioidosis that 
would in turn provide a platform from which rational vaccine design could be 
implemented. 
1.3 ImmunoprophyJaxis 
The first accounts of the use of immunoprophylaxis date to about 1000 AD in China 
(65) where the scabs from smallpox patients that were only mildly affected by disease 
were used to intranasally inoculate healthy individuals (125). The process was known 
as variolation and was fairly successful in comparison to the number of victims of 
natural smallpox infection (65). Vaccine research began during the late 18th century 
(107,108) and progressed, sometimes using questionable techniques, over the next 
century leading to the production of vaccines with variable efficacy, against anthrax 
(154,155), cholera, tuberculosis, typhoid (125), rabies (153) and yellow fever (210,211). 
The advent of molecular biology as a scientific discipline radically altered vaccine 
research and development, with the ability to screen entire proteomes, and even more 
recently genomes for immuno-stimulatory proteins enabling a much more rapid and 
rational approach to vaccine development. Together with this improved efficacy, 
modem day techniques have also enabled improvements in safety, in an increasing 
number of examples, by removing the need for the use of whole cell killed or attenuated 
vaccines. 
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Of equal importance to the identification of immunogenic proteins as vaccine 
candidates is the formulation in which they are delivered. As discussed, different 
activation stimuli can have a profound effect on the type of immune response generated 
highlighting the need to both target the appropriate cell type with the antigen of choice 
and stimulate the right type of immune response to achieve protection against the 
infectious agent. 
1.3.1 Rational vaccine design 
The ultimate goal of a vaccine is to induce long-term immunological memory. Until the 
early 1990's vaccine programs often failed to effectively prime cellular responses to 
provide protection against disease, rather focusing on inducing high antibody titres 
(reviewed in (64». This strategy had until recently been successful because the 
pathogens being targeted either did not cause chronic infections or were antigenically 
stable. Thus the need to understand the mechanisms of cellular immunity has arisen 
from a requirement to develop vaccines against persistent, chronic and intracellular 
infections (64). 
The primary goal of vaccination is to prime the immune system enabling the host's 
immune system to respond more rapidly and effectively following infection than would 
normally be the case after first encountering a pathogen. Thus rational vaccine design 
requires consideration of the protective immune response, the nature of the immunising 
antigen, route of exposure, dose and adjuvants to be used. Once the antigen or antigens 
have been identified consideration then needs to be given to the appropriate route and 
mechanism of delivery that will induce the optimal immune response (64). 
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1.4 Dendritic cell immunotherapy and prophylaxis 
1.4.1 Dendritic cells as adjuvants for immunisation 
The modulation of immunity is an important goal in the treatment and prevention of 
infectious diseases. Several methods have been employed in attempts to enhance or 
suppress specific immune responses. These include; the administration of antigens 
encoded by DNA or viral vectors together with adjuvants, heat shock proteins or 
cytokines (reviewed in (168», the adoptive transfer of antigen-specific T celIs, or the 
use of monoclonal antibodies (reviewed in (17». 
DC, as discussed, are initiators and modulators of immune responses against microbial, 
tumour and self-antigen (12) and the most efficient APC capable of initiating primary 
immune responses. FolIowing experiments by Inaba et al (99), which showed that the 
injection of ex vivo antigen pulsed DC sensitised normal mice to protein antigens, it was 
suggested that DC might be used directly as a vaccine thus avoiding problems with 
variable in vivo targeting. The immunogenicity of antigens delivered on DC was later 
demonstrated in human studies involving the single subcutaneous injection of 2-4 x 106 
antigen-pulsed DC, which led to the rapid expansion of CD 4+ and CD 8+ T cell 
immunity. A subsequent boost several months later led to the expansion of cytotoxic T 
celIs with increased affinity against viral peptide, an observation never made with any 
other vaccination strategy (57,58). 
Several clinical studies have now been published usmg DC-based immunotherapy 
although the vast majority of these are in cancer patients (reviewed in (71». Studies 
focused on the use of DC-based immunotherapy in chronic infectious diseases such as 
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human immunodeficiency virus infection are far fewer and have as yet not yielded such 
encouraging results (71). 
In contrast, studies in healthy volunteers have repeatedly demonstrated the 
immunogenicity of DC. The subcutaneous administration of mature DC pulsed with 
tetanus toxoid, keyhole limpet haemocyanin and human leukocyte antigen restricted 
influenza matrix protein, has been shown to prime individuals to each of the pulsing 
antigens (58). Immune responses were seen to peak one to three months following 
injection declining between six and nine months. The maintenance of memory was also 
established following the re-injection of pulsed DC, which resulted in greater, more 
rapid and higher avidity CD 8+ T cell responses (57). 
In mice, the use of DC as vaccine delivery vehicles has also been demonstrated. 
Worgall et al (2001) (230) showed that immunisation with Pseudomonas aeruginosa 
pulsed DC stimulated a CD 4+ T cell dependent cell-mediated immune (CMI) response 
although no antibody production was noted following DC immunisation. They also 
demonstrated that immunisation with P. aeruginosa pulsed DC afforded an increased 
survival rate in 45% of the population following subsequent intrapulmonary challenge 
with P. aeruginosa (230). Potent type 1, protective responses have also been 
demonstrated against chlamydial genital tract infection following immunisation with 
DC pulsed ex vivo with killed Chlamydiae (200). In this case immunisation with DC 
represents the best vaccine available for prevention of disease and achieves levels of 
protection equivalent to that following infection. In contrast however, Shaw et al 
(2002) (185) later demonstrated a CD 4+ T cell response following immunisation with 
DC pulsed with a chlamydial outer membrane protein, which was type 2 in nature and 
failed to provide protection against disease. This switch in immunity and loss of 
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protection highlights the need for rational vaccine design and demonstrates the 
importance of the nature of the antigen used on the final Th 1-Th2 balance of the 
immune response in vivo (185). 
1.4.2 Potential problems associated with dendritic cell vaccination 
Although to date no significant toxicities relating to DC immunisations have been 
reported (17), a few potential concerns have been highlighted. One such concern is the 
development of autoimmunity following immunisation with DC pulsed with shared 
antigens of tumour and self cells. Most examples of this have been low-grade reactions 
although auto immune syndromes have been reported (131). In addition, allergic 
reactions to bovine albumin following administration of foetal bovine serum cultured 
DC have been documented (131), thus suggesting the need for investigations into serum 
free culture conditions for DC to be used in immunotherapies. There is also the risk of 
viral contamination, especially retroviral, of cultured DC, which may then infect the 
patient rather than having the desired prophylactic effect. Beside clinical problems, 
another issue is the ability to generate the large numbers of DC needed for large-scale 
immunisation. Although rapidly advancing, current culture systems are presently 
inadequate for such a task suggesting the need to develop strategies that can provide 
protective immune responses with minimum amounts of vaccine and limited boosting 
(11). Approaches aimed at overcoming this problem include the use of DC-poietins, 
cytokines that mobilise DC in vivo, and 'intelligent missiles', which are generic 
vaccines containing immunogens, and DC activation molecules that together can be 
targeted to specific DC subsets (11). 
DC are attractive targets for the therapeutic manipulation of the immune system (11). 
Whilst their plasticity can provide a platform from which host immunity could be 
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guided to produce the best response for the infectious disease being targeted, their 
suitability over other vaccination regimens still remains to be proven (17). 
1.5 Project objectives 
The need for an efficacious vaccine against melioidosis is increasingly highlighted, as 
complications in treatment become more prevalent (229). A number of approaches to 
vaccination are currently under investigation, the most successful of which have 
involved the use of an attenuated mutant of B. pseudomallei (8) or passive protection 
through the use of mono clonal antibodies (112). The effectiveness of passive protection 
as a technique, whilst initially good, is reduced over time as circulating antibody levels 
wane. It also fails to stimulate immunological memory meaning it is unsuitable as a 
vaccination strategy due to the high logistical burden imposed by the requirement for 
repeated immunisations. The use of live attenuated bacteria is an approach to 
vaccination used since the beginnings of vaccine research. The success of these studies 
for B. pseudomallei infection suggests that further characterisation of the protective 
immune response is likely to provide a rational basis for design and aid future vaccine 
development work on the disease. 
The intracellular nature of B. pseudo mallei suggests the need for the development of 
long-term cell-mediated immunity in protection against infection. Thus, in this project, 
DC were selected for investigation as a delivery vector capable of stimulating a strong 
CMI response. Herein the potential of DC to fulfil this role is evaluated and the 
appropriateness of their use for B. pseudomallei infection considered. The question of 
rational vaccine design is also addressed through work that begins to elucidate the role 
of type 1 and type 2 immunity in protection against B. pseudomallei infection. 
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2.1 Isolation and culture of primary cells 
2.1.1 Experimental animals 
Female BALB/c mice (10-12 weeks old) were obtained from Charles River Ltd, UK. 
All animals were housed at Dstl, Porton Down under specific pathogen free (SPF) 
conditions with free access to food and water. All procedures were carried out in 
accordance with the requirements of the Animal (Scientific Procedures) Act 1986. 
2.1.2 Isolation oflympbocyte populations from murine spleen 
Spleens were isolated and placed in RPMI-1640 (Sigma, UK) for transport to a class 11 
microbiological safety cabinet. In the cabinet, spleens were gently passed through 
sterile 70 J..lm nylon sieves (BD Falcon, UK) to create a single cell suspension and the 
splenic capsule discarded. After washing by centrifugation at 300g for 10 minutes and 
discarding the supernatant, the cell pellet was re-suspended in 5 mL sterile complete 
medium. Complete medium comprised, RPMI-1640 containing 10% heat inactivated 
foetal bovine serum; HI FBS (Sigma, UK), 1 % penicillin I streptomycin I glutamine; 
PSG (Sigma, UK) and 50 J,lM 2-mercaptoethanol; 2-ME (Sigma, UK). The cell 
suspension was layered onto 3 mL lymphocyte separation medium (LSM) (MP 
Biomedicals, Europe) and centrifuged at 800g for 30 minutes with no braking to prevent 
mixing during the deceleration phase. After centrifugation, lymphocytes were visible as 
a band of cells at the interface between the LSM and complete medium. These cells 
were removed using a plastic pipette, washed by centrifugation at 300g for 10 minutes 
and then a viable count performed using an ethidium bromide I acridine orange stain, 
before proceeding to magnetic separation. The counting medium was prepared by 
adding ethidium bromide and acridine orange to sterile phosphate buffered saline (PBS) 
at a final concentration of5 J..lg mL-1 and 3 J,lg mL-1 respectively. 
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.2.1.3 T cell separation from splenocyte cultures 
The separation ofCD4+ and CDS+ T cells for further use was achieved using the magnet 
assisted cell separation (MACS) kit specific for each population. Cell isolation kits and 
all reagents were purchased from Miltenyi Biotech, UK. All procedures were carried 
out in accordance with the manufacturer's instructions unless otherwise stated. 
2.1.4 Isolation and culture of myeloid dendritic cells from bone marrow 
progenitor cells 
The method for the culture of myeloid dendritic cells (DC) was developed from 
established methods (100,130,183,204). Mice were culled by cervical dislocation and 
the tibiae and fibulae excised using scissors and forceps. Excess tissue was removed 
before the bones were sterilised with 70% ethanol and placed in complete medium for 
transport to a class 11 microbiological safety cabinet. In the cabinet the bone epiphyses 
were removed and the bone marrow flushed from the shafts with complete media using 
a 25-gauge needle and syringe. Gentle pipetting was then used to break up any bone 
marrow pellets and the cells then washed by centrifugation at 300g for 10 minutes. 
Following washing, the cell pellet was re-suspended and a viable count was performed 
with an ethidium bromide I acridine orange stain. The cell concentration was then 
adjusted to 2 x 106 cells mL') in complete medium. 
Granulocyte-macrophage colony stimulating factor (GM-CSF) (R&D Systems, Europe) 
at 20 ng mL') and tumour necrosis factor-alpha (TNF-a) (R&D Systems, Europe) at 10 
ng mL') were routinely added to the cell suspensions. Additional cytokines, interlukin-
(IL-) 4 and IL-12 (both obtained from R&D Systems, Europe) were added to DC 
cultures at a final concentration of 10 ng mL')during experiments to determine optimum 
DC culture conditions. The final cell suspension containing the appropriate cytokines 
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was then plated out into 6-well tissue culture plates (Sterilin, UK) at 2 mL per well and 
the plates incubated at 37°C in a fully humidified environment in the presence of 5% 
C02 for 4 days. 
On day four of the culture the plates were removed from the incubator and the cells 
gently scraped from the well surface. The suspension was then pooled, centrifuged at 
300g for 10 minutes and re-suspended in 5 mL of complete medium per 6-well plate. 
The suspension was layered in 10 mL aliquots onto 2 mL of 13.7% (w/v) metrizamide 
(Sigma. UK). Metrizamide was prepared prior to use by adding 7.25g metrizamide to 
45 mL RPMI-I640 containing 1% PSG. Once dissolved, 5 mL of HI FBS was added to 
the metrizamide, which was then separated into 2 mL aliquots and stored at -20°C until 
use (133). Once layered onto the metrizamide, the cells were centrifuged at 800g for 10 
minutes with no braking to prevent any mixing during the deceleration phase. After 
centrifugation the DC were visible as a band of cells at the interface between the 
metrizamide and the culture medium that could be easily removed using a plastic 
pipette. After isolation, the DC were washed twice by centrifugation at 300g to ensure 
all metrizamide was removed from the cells, counted using an ethidium bromide / 
acridine orange stain, and re-suspended ready for use. 
2.2 Phenotypic analysis of cells 
2.2.1 Flow cytometry 
Flow cytometric analysis was used to characterise cell populations. Cells to be analysed 
were washed by centrifugation at 300g for 10 minutes and pellets were re-suspended in 
buffer (phosphate buffered saline containing 2.5% HI FBS). Cells were then washed 
again and re-suspended in fresh buffer at a concentration of 1 x 107 mL-I• Aliquots of 
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cells (lOO ilL) were pipetted into polystyrene flow cytometry tubes (BD Falcon, UK) 
and Fc block (anti-CD 16/ CD 32) (BD Biosciences, Pharmingen, International) added 
to each tube at a concentration of 1 J.lg per 1 x 106 cells. Antibodies appropriate to the 
investigations being undertaken were then added to each tube. Antibodies obtained 
from BD Biosciences, Pharmingen, International and Serotec, UK were used as 
described in table 2.1. For staining, cells and antibodies were incubated together for 30 
minutes at 2-8°C. Further antibody binding was then halted by the addition of 4% 
paraformaldehyde to each tube to fix the cells. Cells were fixed for at least 1 hour at 2-
8°C and stored for no longer than 72 hours before analysis. 
In all flow cytometry studies corresponding isotype controls were used to establish 
quadrants and / or regions for analysis. Analyses were performed using Cell Quest Pro 
flow cytometry analysis software. 
Supplier Coupled fluorochrome Concentration (UI! oer 1 x 106 cells) 
BD Biosciences FIuorescein isothiocyanate (FITC) 1.0 
Pharmingen 
BD Biosciences R-phycoerythrin (R-PE) 0.2 
Pharmingen 
BD Biosciences Peridinin chlorophyl-a protein 0.2 
Pharmingen (PerCP) 
BD Biosciences R-PE-Cychrome (Cy) 5 0.2 
Pharmingen 
BD Biosciences PerCP-Cy 5.5 0.2 
Pharmingen 
Serotec, UK FITC 5.0 
Serotec, UK R-PE-Cy 5 2.0 
Table 2.1 Flow cytometric nuorochromes 
Fluorochromes used for flow cytometry analysis and the concentrations at which they were used. 
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2.3 Culture of Burkholderia pseudomal/ei 
2.3.1 Culture of viable Burkholderia pseudomal/ei 
All procedures involving the culture of viable B. pseudomallei were performed under 
ACDP category III conditions. Stock B. pseudomallei (NCTC 4845) was previously 
prepared by Mr Tony Stagg and Mr Richard Beedham (Biomedical Sciences, Dstl, 
Porton Down) (Stagg, A. J., personal communication) and stored at -80°C on protect 
beads (Technical Service Consultants Ltd, UK). Cultures were prepared by adding five 
beads to 10 mL nutrient broth and incubating at 37°C for 24 hours in a static culture. 
This culture system has been shown to typically yield 1 x 108 cfu mL- t (Stagg, A. J., 
personal communication) and thus for the purpose of calculating challenge doses such a 
yield was assumed. 
Accurate viable counts were obtained by setting up serial dilutions of the culture and 
preparing spread plates using 100 J.lL aliquots of the serial dilutions on nutrient agar (in 
triplicate). Once spread, plates were incubated at 37°C overnight before manual 
enumeration of the number of colony forming units (cfu). A dilution was then chosen at 
which between 20 and 200 cfu were present on the plates and a mean colony count 
determined from the triplicate. The original stock concentration was then calculated 
using the equation below: 
Number of cfu mL- t = Mean cfu x 10 x dilution factor 
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2.3.2 Heat inactivation of Burkholderia pseudomal/ei 
Heat inactivation was kindly performed by Ms Michelle Nelson (Biomedical Sciences, 
Dstl, Porton Down). 
Bacterial cells were harvested by centrifugation and washed three times in PBS, before 
re-suspending in one tenth the original volume ofPBS. The suspension was then placed 
in a-ring sealed centrifuge tubes (Sorvall, Connecticut, USA) in a water bath at 80°C 
for 3 hours, with occasional shaking. Following inactivation, the suspension was 
checked for viability by inoculating 10 mL volumes of nutrient broth with 0.5 mL 
aliquots of the suspension to a total volume of 5 mL or 10% of the total volume 
(whichever was smaller) and incubating at 37°C for seven days. Nutrient agar plates 
were then inoculated with the total volume of the broth cultures and incubated at 37°C 
for a further seven days to check for bacterial growth. If no growth occurred on the 
agar plates the bacterial suspension was considered inactivated. 
2.4 Characterisation of the cellular immune response to 
BurkllOlderia pseudomallei 
2.4.1 Maturation of dendritic cells 
Dendritic cells were cultured and purified as described in 2.1.4. The cells at a 
concentration of 2 x 106 mL·1 were transferred to 24-well tissue culture plates in 1 mL 
aliquots and 'rested' for 24 hours at 37°C in a fully humidified atmosphere in the 
presence of 5% CO2• After 'resting', the desired maturation stimuli were added to the 
DC at the appropriate time points; TNF-a at 50 ng mL·1, lipopolysaccharide (LPS) at 10 
J..lg mL-1 or heat killed (HK) B. pseudomallei at 1 x 107 cfu mL-1• After co-culture for 
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the desired length of time, cells were removed from the wells and stained for flow 
cytometric analysis (see 2.2.1) before fixing and storage at 2-8°C. 
2.4.2 Primary (naive) Lymphocyte proliferation assays 
Dendritic cells were cultured and purified as described in 2.1.4. HK B. pseudomal/ei 
was then added to the culture at the desired concentration and incubated with the DC for 
18 hours at 37°C in a fully humidified atmosphere in the presence of 5% CO2• After 
incubation, the DC were washed by centrifugation at 300g for 10 minutes. The 
supernatant was discarded and the pellet re-suspended in fresh complete medium. This 
was repeated twice to ensure any extracellular antigen had been removed and the DC 
were finally re-suspended to a concentration of 5 x 105 cells mL-1 in complete medium 
without cytokines. 
Spleens from naIve mice were removed and gently passed through sterile 70 f.,lm nylon 
sieves (BD Falcon, UK) into complete medium. The suspension was centrifuged at 
300g for 10 minutes and the supernatant discarded. Three mL of sterile 0.85% 
ammonium chloride (Sigma, UK) was added to the cell suspension, which was then 
incubated for 5 minutes at room temperature with occasional agitation to ensure 
thorough mixing. After incubation the cells were washed twice by centrifugation at 
300g for 10 minutes to remove any ammonium chloride. After the final wash the cells 
were counted and re-suspended to a concentration of 5 x 106 cells mL-1• 
The splenocyte suspension and antigen-pulsed DC were plated out in 100 f.,lL aliquots. 
Unstimulated DC, HK B. pseudomallei alone and complete medium alone were used as 
negative controls and Concanavalin A (Con A) (Sigma, UK) at a final concentration of 
1 f.,lg mL-1, was used as a positive control in all assays. 
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Plates were incubated at 37°C in a fully humidified environment in the presence of 5% 
C02 for 1 - 6 days depending on the experiment being performed. After the required 
incubation period 37 MBq (1 J!Cu) methyl-tritiated thymidine (Amersham Biosciences, 
UK) was added to each well on the plates, which were then returned to the incubator for 
a further 24 hours. After this incubation, the cells were harvested onto 96-well GF-C 
filter microplates (PerkinElmer Life Sciences, UK) using an automated cell harvester 
(PerkinElmer Life Sciences, UK) and allowed to dry overnight. Once dry, 20 J!L of 
scintillation liquid (Amersham Biosciences, UK) was added to each well of the filter 
plate and the degree of methyl 3H-thymidine incorporation measured using a microplate 
scintillation counter (PerkinElmer Life Sciences, UK). 
Data were presented as mean counts per minute (CPM), which is calculated from the 
mean of five replicates from pooled lymphocytes from five separate spleens, ± standard 
error of the mean (SEM). 
2.4.3 Secondary (recall) Iymphocyte proliferation assay 
2.4.3.1 Unseparated splenocyte proliferation 
Splenocytes for memory proliferation assays were prepared in the same manner as those 
in 2.4.2. Spleens from immunised mice were used to assess the degree of memory 
proliferation and splenocytes from naive animals were used as controls. Once prepared, 
the Iymphocyte suspensions were plated out in 100 J!L aliquots. The antigen against 
which the memory response was being investigated was prepared to twice the optimum 
concentration in complete medium and then added to the appropriate wells on the assay 
plate in 100 J!L aliquots. Lymphocytes from naive spleens were used in all assays as a 
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negative control. Complete medium only and HK B. pseudomal/ei only negative 
controls and Con A positive controls were also included on all plates. Plates were 
incubated at 37°C in a fully humidified environment in the presence of 5% CO2 for 1-6 
days as required. The degree of lymphocyte proliferation was then assessed by the 
incorporation of methyl 3H-thymidine as described in 2.4.2. 
2.4.3.2 Purified T cell proliferation 
Antigen-pulsed DC were prepared as described in 2.4.2 and isolated Iymphocyte 
populations were prepared from immunised animals as described in 2.1.2 and 2.1.3. 
Once isolated, Iymphocyte populations were centrifuged at 300g for 10 minutes to 
remove the isolation medium and re-suspended to a concentration of 2.5 x 106 cells mL" 
I in complete medium. DC and lymphocytes were then aliquoted into 60-well terasaki 
plates (Greiner Labortechnik Ltd, UK) in 10 ilL volumes. Lymphocyte only, DC only 
and complete medium only negative controls were included on each plate. Con A at a 
final concentration of 1 Ilg mL-) was included as a positive control. Nai've Iymphocytes 
were also incubated with HK B. pseudomal/ei pulsed DC and the data included for 
comparison. Plates were inverted to allow cells to converge at the bottom of the 
medium drop in each well, and incubated in a fully humidified atmosphere at 37°C in 
the presence of 5% C02 for 4 days. 
After incubation, 37 MBq (1 IlCU) methyl 3H-thymidine was added to each well and the 
plates returned to the incubator for a further 24 hours. Cells were then transferred to the 
wells of a 96-well tissue culture plate containing 100 ilL complete medium, harvested 
and counted as described in 2.4.2. Data from these assays was presented as the mean 
stimulation index (SI), tSEM. This was due to the fact that the assays required multiple 
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proliferation plates to be set up on a weekly basis rather than all at the same time. All 
plates were set up with the appropriate negative control (naive unstimulated T cells), 
which was used to calculate the SI: 
SI = CPM of test 
CPM of negative control 
Mean SI was derived from four replicates of the pooled lymphocytes of two test 
subjects. 
2.5 Cytokine analysis 
2.5.1 Cytometric Bead Array 
Cytokine analysis of serum and supematant samples was carried out using Cytometric 
Bead Array (CBA) kits and was performed in accordance with the manufacturers' 
instructions. Kits used were either the mouse inflammation CBA kit (552364, BD 
Biosciences, UK) or the mouse Thl / Th2 CBA kit (551287, BD Biosciences, UK). 
2.6 Characterisation of the antibody response 
2.6.1 Serum antibody quantification using tbe enzyme linked immunosorbant 
assay (ELISA) 
Assay plates were prepared by coating 96-well ELISA plates (lmmulon 2, Dynex 
Technologies, UK) with the HK B. pseudomallei. Fifty J,lL PBS containing HK B. 
pseudomallei at a concentration of 1 x 106 cfu mL"1 was added to each well of the 
desired number of 96-well plates. Wells to be used for the generation of a standard 
curve were coated with Fab specific mouse IgG at 5 J,lg mL"I. The plates were covered 
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and incubated overnight at 2-8°C. After incubation the plates were washed three times 
with PBS containing 0.02% Tween 20 (Sigma, UK) using a SKATRON-SkanWasher 
400 automated plate washer. 
Blotto (2% (w/v) skimmed milk powder in PBS) was added to each well in 200 ilL 
aliquots and the plates blocked for 1 hour at 37°C. After the blocking step plates were 
again washed three times. 
Test samples were diluted 11100 in 2% Blotto and mouse total IgG standard (Sigma, 
UK) was diluted to the optimum starting concentration (100 ng mL-1), also in 2% 
Blotto. After washing, 100 ilL aliquots of the standard (in triplicate) and test samples 
(in duplicate) were added to the appropriate top wells of the plate and 50 J.!I of 2% 
Blotto added to all other wells on the plates. The standard and samples were then 
double diluted down the plate. Plates were covered and incubated at 37°C for 2 hours. 
After incubation the plates were washed and 50 J.!L anti-mouse total JgG-horse radish 
peroxidase (HRP) conjugate (Immunologicals direct, UK) (diluted 1/2000 in 2% Blotto) 
added to each well. Plates were incubated for a further 2 hours at 37°C. After 
incubation the plates were washed for the final time and 100 ilL ABTS substrate - 3 
ABTS tablets (Sigma, UK) in 50 mL citrate buffer + 5 III hydrogen peroxide (Sigma 
UK) - added to each well. The plates were left for 20 minutes for the colour to develop 
and read at 414nm. 
Optical density readings were converted to antibody concentrations using the standard 
curves set up on each ELlSA plate. Analysis was performed using 'Ascent' 
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spectrophotometer analysis software. Results were displayed as mean concentration, of 
five test subjects each assayed in duplicate ± SEM. 
2.7 In vivo experimentation 
All procedures involving the use of B. pseudomallei were carried out under ACDP 
containment level III conditions unless the bacteria had been previously demonstrated 
to be dead. Under such circumstances, procedures were carried out under ACDP 
containment level 11 conditions. 
2.7.1 Dendritic cell immunisation 
HK B. pseudomallei pulsed DC were prepared as described in 2.4.2. Following 
incubation the DC were removed from the incubator and washed by centrifugation at 
300g for 10 minutes, discarding the supernatant and re-suspending the cell pellet in 
sterile PBS. This was repeated twice to ensure any extracellular antigen was removed. 
After the final wash, DC were re-suspended to 1 x 106 cells per I 00 ~L in sterile PBS 
for intra-dermal (ID) immunisation or 2 x 106 cells per 1 00 ~L in sterile PBS for intra-
nasal (IN) immunisation. 
DC administered via the ID route were given in 100 ~L aIiquots (50 ~L into each hind 
leg), while IN immunisation was carried out using 50 ~L aIiquots into the nostrils of 
animals under Halothane (RMB Animal Health Ltd, UK) sedation. 
2.7.2 Immunisation with heat killed Burkholderia pseudomallei 
HK B. pseudomallei were prepared to a concentration of 5 x 104 cfu mL-1 in sterile PBS. 
A vial of MPL + TDM adjuvant system (Sigma, UK) was warmed to 37°C and then 
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reconstituted with 2 mL of the HK B. pseudomallei in PBS preparation. In accordance 
with the manufacturers' instructions the vial was then vortexed for 2 to 3 minutes, 
inverted and vortexed for a further minute before use. Immunisation was performed 
with 100 ilL aliquots of the emulsion (50 ilL into each hind leg), which had cooled to 
room temperature, via the intra-muscular (IM) route. 
2.7.3 Determination of LDso for Burkholderia pseudomal/ei (NCTC 4845) 
Viable B. pseudomallei were prepared as described in 2.3.1 and serially diluted to 
produce a dose range between 10 cfu mL-1 and 1 x 105 cfu mL-1• Aliquots (100 ilL) of 
each of the challenge inocula were then plated out onto nutrient agar (in triplicate) and 
incubated at 37°C overnight to provide accurate counts for the final dose calculation 
(see 2.3.1). 
Groups of 5 female BALB/c mice were challenged with 100 ilL viable B. pseudomallei 
via the intra-peritoneal (JP) route with a challenge dose from the dose range described. 
Animals were closely observed for 35 days following challenge, at which point the 
experiment was terminated and any survivors humanely culled. Time to death and / or 
number of survivors was recorded for each group and the LDso then calculated using the 
method of Reed and Muench (169). 
2.7.4 Burkholderia pseudomal/ei challenge studies 
Viable B. pseudomallei were prepared as described in 2.3. J and diluted to give an 
approximate challenge dose of 1 x 105 cfu mL-1• Challenge was performed with 100 ilL 
aliquots of the challenge inoculum via the JP route. After challenge, mice were closely 
observed for 35 days, at which point experiments were terminated and any survivors 
humanely culled. 
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2.7.5 Assessment of post-challenge bacterial load 
Tissue samples from survivors were collected for bacteriology at day 35 post-challenge. 
Brains, spleens, livers, lungs and blood were taken to provide samples for analysis. 
Organs were passed through 70 Ilm nylon sieves into sterile PBS to create a cell 
suspension and blood diluted 1 in 2 in sterile PBS. Aliquots of 100 ilL of each of the 
tissue samples were then spread onto nutrient agar plates and incubated at 37°C for 24 
hours. After incubation the plates were assessed for bacterial growth and the number of 
colonies manually enumerated. 
2.8 Statistical analysis 
Statistical analyses were perfonned, with the kind assistance of Mr Robert Gwyther 
(Dstl, Biomedical Sciences). Analysis of the mature population of DC following 
culture (section 3.1.2.1) was perfonned using general linear model Analysis Of 
Variance (ANOVA) while all remaining in vitro experiments were analysed using two-
way ANOVA's. The only exception was analysis of the naive in vitro proliferation 
assays (section 3.2.2), which were analysed using a multivariate ANOVA. Analysis of 
the challenge and LDso data was perfonned using PRISM graph pad survival analysis 
software, and p-values calculated using the log rank test for trend. 
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3.1 Growth, manipulation and characterisation of ex vivo isolated 
cells 
3.1.1 Culture of dendritic cells from bone marrow progenitor cells 
DC were initially cultured for 7-10 days in the presence of GM-CSF with media 
changes on days 4 and 8 as described in the literature (183,203). Whilst these systems 
succeeded in generating DC, yields were often not sufficient and removing the DC from 
the culture plates, by dislodging proliferating aggregates, caused a high degree of non-
specific maturation. Using magnetic sorting methods to further purify the cells 
compounded this problem and also induced maturation. 
The method was further refined and TNF-a was added to cultures in an attempt to 
improve yields. The use of metrizamide as a density gradient on which to purify the 
DC was also investigated. The addition of low concentrations (1 ng mL-1) ofTNF-a to 
the culture also significantly improved the culture rate such that proliferating aggregates 
of DC were abundant by day four of the culture (Figure 3.1). Flow cytometric analysis 
of DC at day 4 of the culture following metrizamide purification revealed a cell 
population with a high forward scatter / side scatter profile, which typically constituted 
greater than 80% of the total popUlation (Figure 3.2). Further flow cytometric analysis 
of these cells with a panel of antibodies revealed a phenotype typically expressed by 
myeloid DC; MHC class U++, CD Ilc+, CD 80+, CD 86++, CD 205+, CD lIb+, CD 14+, 
CD 34+, CD 8a+, CD 54+ and CD 40+ (Figure 3.3) (this phenotypic pattern was 
consistently noted in five separate experiments). It also demonstrated that the cell 
population contained a low percentage (typically less than 20%) of contaminating cell 
populations, assessed on the basis of the T cell marker CD 3, the B cell marker CD 19, 
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the macrophage / monocyte marker F4/80 and the granulocyte marker Ly.6G (Table 
3.1). 
Cell Marker Cell Lineage association Percentage expression in 
DC population 
CD3 T cells 4.76% (±0.38) 
CD 19 B cells 1.14% (±0.2) 
F4/80 Macrophages / Monocytes 7.82% (iO.35) 
Ly.6G Granulocytes 7.3% (±0.59) 
Table 3.1 Contaminating (ell populations present in a dendritic cell culture 
Percentage expression of non-dendritic cell lineage cell markers within the metrizamide purified dendritic 
cell population. Contamination by other leukocyte populations was typically approximately 20%. 
Number in parentheses equals standard error of the mean (SEM), calculated from expression observed in 
five separate cultures. 
The effect of adding either IL-4 or IL-12 to the culture was also investigated. The 
addition of either of these cytokines resulted in no notable phenotypic differences to the 
DC population (data not shown). However, while typical cultures with GM-CSF and 
TNF-a (GT), and GM-CSF, TNF-a and IL-4 (GT4) produced yields of between 7 and 
10 x 106 DC per mouse, a pronounced reduction in yield (2 to 3 fold) was noted in all 
cultures including IL-12 (GT12). 
55 
Chapter 3 - Results 
3.1.2 Dendritic cell responsiveness to maturation stimuli 
3.1.2.1 Effect on phenotype 
The proportion of mature to immature DC present in purified DC populations affects 
their ability to process and present antigen. If too high a proportion of the DC were 
already mature before exposure to antigen, their ability to generate an appropriate 
immune response would be hindered as a result of the reduced uptake and processing 
faculties of mature DC. A mature DC phenotype is characterised by high MHC class 11 
expression. The mature proportion of cells observed for the GT and GT12 cultures was 
24.45% and 23.91% respectively, while the GT4 culture produced a mature population 
of 31.05% (Figure 3.4) although this was not found to be significantly greater (p>0.05). 
This experiment was repeated five times and no significant variation was noted between 
experiments (p>0.05). 
The responsiveness of the DC population to maturation stimuli was investigated, which 
allowed the establishment of their suitability for further experimentation. DC cultured 
under the three cytokine conditions, GT, GT4 and GTI2, were exposed to either the 
inflammatory cytokine, TNF-a., or the bacterial cell wall component, 
lipopolysaccharide (LPS) from Salmonella typhimurium. Cell maturation status was 
assessed on the basis of high MHC class 11 expression in addition to high expression of 
the co-stimulatory molecules CD 80 and CD 86 and the cell adhesion molecule CD 54, 
at 6, 24 and 48 hours post-exposure. Increased expression of MHC class 11, CD 80, CD 
86 and CD 54 is associated with DC maturation and is essential for the interaction with, 
and stimulation of naiVe T cells. Figures 3.5 to 3.7 illustrate the effect of each 
maturation stimulus on DC cultured in each of the cytokine environments compared to 
control unstimulated DC. 
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For DC cultured in the GT cytokine environment (Figure 3.5), exposure to TNF-a 
induced an increase in the percentage of MHC class 11 and CD 86 bright cells after 6 
hours, which continued increasing to 48 hours post exposure. An increase in the 
percentage of CD 54 bright cells was noted 24 hours after exposure, which increased 
further after 48 hours. No increase in the percentage of CD 80 bright cells was 
observed. A similar pattern of expression was noted for MHC class 11, CD 86 and CD 
54 following exposure to LPS. In addition, an increase in the percentage of CD 80 
bright cells was observed, which was at its greatest 48 hours post exposure. 
This pattern of marker expression over the 48 hours post exposure was also observed 
for DC cultured in the GT4 and GTl2 cytokine environments (Figures 3.6 and 3.7 
respectively), although the final percentages of expression varied. The only exception 
to this was exposure of the GT12 cultured DC to TNF-a. This population initially 
showed an increase in the percentage of MHC class 11, CD 86 and CD 54 bright cells up 
to 24 hours post-exposure, which was followed by a reduction in the percentage of 
bright cells for each marker by 48 hours. 
3.1.2.2 Effect on cytokine secretion 
At each of the flow cytometric analysis time points, supernatant samples were taken and 
analysed for the cytokines IFN-y, IL-5, IL-2, IL-lO and IL-6. Concentrations observed 
at 6, 24 and 48 hours after exposure were normalised against that observed from control 
unstimulated DC. No increase in IL-6 secretion was noted for any of the DC groups 
(GT, GT4 or GT12) and although assessed in later experiments, IL-4 and IL-12p70 
concentrations were not measured due to the inability to distinguish between cytokine 
added to the culture and cytokine secreted by the DC. For the GT cultured DC (Figure 
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3.8), stimulation with TNF-a resulted in a significant increase in IL-tO (p<O.05) by 24 
hours post-exposure. An increase in IL-2, IL-5 and IFN-y secretion was also observed 
by 24 hours although these were not found to be significant (p>O.05). Exposure of the 
GT cultured DC to LPS produced a similar pattern of cytokine secretion although there 
was an approximately two-fold increase in IL-lO secretion (p<O.05). Again, increases 
in IL-2, IL-5 and IFN-y secretion were not found to be statistically significant. 
Exposure of the GT4 cultured DC to TNF-ex induced an initial increase in IL-IO 
secretion (p<O.05), which fell by 24 hours post-exposure. Increases in IFN-y, IL-2 and 
IL-5 were not significant. Exposure ofthis group to LPS led to a significant increase in 
IFN-y and IL-IO secretion by 24 hours post-exposure (p<O.05) compared to control 
unstimulated DC. IL-lO secretion was also noted to increase in the GT12 group 
following exposure to LPS, which had the greatest level ofIL-IO secretion (p<O.Ol) 48 
hours post-exposure. Increases in the other cytokines following LPS exposure and all 
cytokines foHowing TNF-a exposure were not found to be significant (p>O.05). 
3.2 In vitro immune responses to BurkllOlderia pseudomallei 
3.2.1 Dendritic cell maturation following exposure to heat killed Burkholderia 
pseudomal/ei 
3.2.1.1 Effect on morphology and phenotype 
Following successful establishment of DC responsiveness to maturation stimuli, their 
responsiveness to B. pseudomallei was assessed. An important step in the ability of DC 
to 'deliver' B. pseudomallei associated antigens to nai've T cells and generate a 
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protective immune response, is their ability to respond to the bacteria and undergo 
maturation. Maturation status was determined by the cell surface expression of MHC 
class 11, CD 80, CD 86 and CD 205 at 0, 12, 24, 48, 72 and 96 hour time points. The 
maturation response to HK B. pseudomallei was more rapid than that observed to TNF-
a and LPS, with significantly increased cell surface expression of all four markers 
noted by 12 hours post exposure (p<O.OI) (Figures 3.11 and 3.12). Continued culture in 
the presence of HK B. pseudomallei over the next 84 hours demonstrated that the 
mature population of DC, identified by high expression (bight fluorescence) of the four 
markers, persisted throughout the culture (figure 3.13). 
In addition to flow cytometric analysis, morphological responses to B. pseudomal/ei 
exposure were observed using phase contrast microscopy over the first 24 hours of the 
culture. Figure 3.14 demonstrates the resulting morphological changes of the DC 
following exposure to HK B. pseudomal/ei. Elongation of the DC can be seen by 3 
hours post exposure. A mature DC morphology with the presence of long dendrite like 
projections was apparent by 18 hours post exposure, and a gradual increase in mature 
morphological phenotype can be seen over the remainder of the 24-hour observation 
period. 
3.2.1.2 Effect on cytokine secretion 
Supernatants from DC exposed to HK B. pseudomallei were assayed for the presence of 
IFN-y, IL-5, IL-4, IL-2, IL-12p70, IL-to and IL-6. Figures 3.15 and 3.16 show the 
cytokine secretion profile of DC 12 hours (the time at which phenotypic maturation was 
observed) after exposure to HK B. pseudomallei compared to control unstimulated DC. 
IL-6 is depicted in a separate graph due to the much larger scale required for this 
cytokine. An increase in all cytokines assayed was noted except IL-4, which did not 
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increase above control levels. Significant increases in IL-lO (p<0.05), IL-6 (p<O.O I) 
and IL-12p70 (p<0.05) were noted compared to control unstimulated DC. 
3.2.2 In vitro Jymphocyte proliferation to heat killed Burkholderia pseudomalle; 
The ability of the DC population to present B. pseudomallei associated epitopes to naiVe 
T cells was next assessed. Proliferation assays were optimised by varying both the 
concentration of HK B. pseudomallei to which the DC were exposed and the ratio of 
DC to lymphocytes. Figure 3.17 demonstrates the proliferative responses of naIve 
lymphocytes to a range of stimulation conditions. For all concentrations of HK B. 
pseudomallei and DC to lymphocyte ratios investigated, the proliferative response was 
significantly greater than that of the negative control (p<O.OO 1). For all concentrations 
of HK B. pseudomallei, except 1 x 106 cfu mL· l , the greatest proliferative response was 
seen with a DC to lymphocyte ratio of 1 to 10. Multivariate analysis of variance 
revealed that this ratio produced significantly greater proliferation (Mean Log CPM = 
3.703,95% Cl = 3.685 to 3.721) as compared to the 1 to 100 (Mean Log CPM = 3.605, 
95% Cl = 3.589 to 3.622) and 1 to 1000 (Mean Log CPM = 3.340, 95% Cl = 3.323 to 
3.358) ratios. Analysis of the different concentrations investigated revealed that the 
greatest level of proliferation observed was for the concentration I x 104 cfu mL-l (= 5 x 
103 cfu per I x 106 DC) (Mean Log CPM = 3.668, 95% Cl = 3.647 to 3.689). This 
concentration was observed to elicit significantly greater proliferative responses 
(p<0.05) compared to the other concentrations investigated except I x 107 cfu mL- l 
(Mean Log CPM = 3.632, 95% Cl = 3.611 to 3.653), which was not found to be 
statistically different. Analysis of the proliferation observed over each of the six days 
of the proliferation assays, demonstrated that optimum proliferation was observed after 
four days of co-culture (Mean Log CPM = 3.697, 95% Cl = 3.673 to 3.721), and this 
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proliferation was found to be significantly different from that measured on other days of 
the assay (p<0.05). 
On the basis of these data a pulsing concentration of 1 x 104 cfu mL-1 was selected and 
used for all future studies. 
3.3 Characterisation of immune responses to dendritic cell 
immunisation 
Having successfully established the ability of the DC to generate primary immune 
responses to B. pseudomallei associated antigens in vitro, the immune responses 
generated following immunisation with HK B. pseudomallei pulsed DC were 
characterised. Review of the literature had suggested that successful in vivo immune 
responses to DC immunisation took four to five weeks to become established (17,119). 
Thus, an immunisation regimen of prime at day 0 and boost at day 28 was chosen to 
allow for such a lag phase in the establishment of an adaptive immune response. 
Intradermal (ID) and intranasal (IN) administration routes were investigated. 
3.3.1 Investigation of cellular memory responses 
Groups of five mice were immunised with either DC pulsed with HK B. pseudomallei, 
via the ID route, or HK B. pseudo mallei delivered in MPL + TDM, via the 
intramuscular (lM) route. Immune memory status was assessed four weeks following 
the priming dose (Figure 3.18) and then five weeks after the booster dose (Figure 3.19), 
which gave an indication of the immune status at the point of challenge. Memory 
responses following priming with HK B. pseudomallei in MPL + TDM peaked after six 
days of culture at which point responses were significantly greater (p<0.05) than the 
level of proliferation seen for the nai've control group. Immunisation with a priming 
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dose of HK B. pseudomallei pulsed DC stimulated a significantly greater memory 
response (p<O.OOI) than that observed following immunisation with HK B. 
pseudoma/lei in MPL + TOM, which was also much more rapid, peaking after four days 
of culture. Memory responses following the booster dose were more rapid for both the 
test groups. Proliferation for the group primed and boosted with HK B. pseudomallei in 
MPL + TDM was greater (p<0.05) than that seen after the priming dose and also peaked 
a day earlier at five days after culture. While no significant difference was observed in 
the level of memory proliferation seen in the group primed and boosted with HK B. 
pseudomallei pulsed ~C, proliferation was noted to peak a day earlier after the booster 
dose at three days of culture demonstrating a faster recall response. These initial data 
therefore suggested that the regimen chosen was suitable for the generation of a rapid 
recall response. 
3.3.2 Investigation of humoral responses 
In addition to cellular responses, humoral responses were also investigated following 
immunisation (Figure 3.20). Immunisation with HK B. pseudoma/lei delivered in MPL 
+ TOM (IM) induced a strong anti-B. pseudoma/lei antibody response, which was 
significantly greater than both the DC immunised (ID) and nai've groups (p<0.05) after a 
single immunisation. Boost immunisation with HK B. pseudomallei in MPL + TOM 
(IM) at day 28 augmented the response to approximately two-fold the levels achieved 
after the priming dose. No antibody production was observed following immunisation 
with HK B. pseudomallei pulsed DC above that seen in the nai've group at either time 
point. 
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3.3.3 Attempt to establish a balanced immune response and investigation of the 
intradermal and intranasal delivery routes. 
Despite the successful establishment of a strong cellular recall response following 
immunisation with pulsed DC, protection against virulent B. pseudomallei challenge has 
been demonstrated using HK B. pseudomallei delivered in MPL + TDM (8,112), which 
suggested that antibody may play a role. Thus the immunisation regimen was altered 
such that an additional group of mice was primed with HK B. pseudomallei pulsed DC 
at day 0 and then boosted with HK B. pseudomallei delivered in MPL + TDM at day 28. 
The aim of this modification was to establish a balanced immune response following 
immunisation, which would generate both humoral and cellular responses upon 
challenge. The effect of delivering the DC via the IN route was also investigated to 
compare any differences observed. 
Figures 3.21 and 3.22 show a comparison of the cell mediated and humoral immunity at 
day 63 (five weeks after the booster dose) for each of the immunisation groups 
following either ID or IN delivery of the DC respectively. HK B. pseudomallei 
delivered in MPL + TDM was administered via the IM route only and the group that 
received two doses of this formulation is included on both the ID (Figure 3.21) and IN 
(Figure 3.22) graphs for comparison purposes. Following priming with HK B. 
pseudomallei pulsed DC via either the ID or IN, a significantly greater memory recall 
response (p<O.OOI) was observed compared to IM immunisation with HK B. 
pseudomallei delivered in MPL + TDM. Antibody responses for the groups immunised 
with two doses of HK B. pseudomallei in MPL + TOM (lM) were significantly greater 
than those observed in the groups that received HK B. pseudomallei pulsed DC 
(p<O.05) via either the ID or IN route. 
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For the group primed with HK B. pseudomallei pulsed DC via the IN route, substitution 
of the day 28 DC dose with a dose of HK B. pseudomallei delivered in MPL + TDM 
afforded no significant changes in either the cellular or antibody responses observed 
(p>O.05). For the group primed with HK B. pseudomallei pulsed DC via the ID route 
however, a significant increase in antibody production was observed (p<O.05) when the 
day 28 DC dose was substituted with a dose ofHK B. pseudomallei delivered in MPL + 
TDM (compared to the group that received two doses of HK B. pseudomallei pulsed 
DC). No significant change in the cellular recall response was observed as a result of 
this substitution (p>O.05). 
3.4 Protective efficacy of dendritic cells as a vaccine delivery vector 
3.4.1 Determination of the LDso for virulent Burkholderia pseudoma/lei (NCTC 
4845) 
Before proceeding to challenge experiments to test the efficacy of DC immunisation, a 
nai"ve challenge experiment to determine the LDso via the IP route for the strain of B. 
pseudomallei being used was performed. Figure 3.23 shows the survival curve for each 
of the challenge groups, together with the mortality data table constructed to allow 
calculation of the LDso. 
Calculation of the LDso was performed as follows in accordance with the method of 
Reed and Muench (169). 
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Interpolated value = 50% - % mortality below 50% 
% mortality above 50% - % mortality below 50% 
:. Interpolated value = 50-0 
80-0 
= 0.625 
Log LD50 = Log dose below 50% mortality + interpolated value 
:. LDso = 10(1·886 + 0.62S) = 324.7 cfu 
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Following calculation of the LDso a target challenge dose of approximately 1 x 104 cfu 
(~ 30 LDso doses) per mouse was chosen to ensure that an acute infection was induced 
following challenge. 
3.4.2 Challenge with virulent Burkholderia pseudomal/ei 
3.4.2.1 Intradermal dosed groups 
Following successful establishment of an LDso and a standardised challenge dose, the 
protective efficacy of DC immunisation was next tested. Mice immunised with either 
HK B. pseudomallei pulsed DC via the ID route, HK B. pseudomallei delivered in MPL 
+ TDM via the IM route or a combination of the two formulations were challenged with 
virulent B. pseudomallei (NCTC 4845) injected into the peritoneal cavity (JP route) 
(Figure 3.24). Due to the inability to quantify challenge doses prior to challenge, mice 
were challenged with 5.3 x 104 cfu (163 LDso) rather than the target challenge dose of 1 
x 104 cfu. Animals were closely observed for 35 days following challenge, during 
which time any animals showing signs of severe illness were humanely culled. 
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All naIve mice died on day 10 post challenge. All mice primed and boosted with HK B. 
pseudomallei pulsed DC died by day 16 post challenge. The group primed and boosted 
with HK B. pseudomallei in MPL + TOM displayed a significantly delayed time to 
death and 20% survival rate (p<0.005) compared to the naIve controls. The final group 
primed with HK B. pseudomallei pulsed DC and then boosted with HK B. pseudomallei 
in MPL + TOM displayed a significant delay in time to death and a 60% survival rate 
(p<0.005) compared to the naIve controls. In addition, a significant increase in time to 
death and survival rate was noted (p<0.005) for this last group when compared to the 
group primed and boosted with HK B. pseudomallei pulsed DC (Figure 3.24). 
Assessment of the remaining bacterial burden (Table 3.3) demonstrated evidence of 
bacterial clearance. One mouse from each of the groups with survivors had no B. 
pseudomallei present in any of the tissues cultured (brain, liver, spleen and blood). 
While the remaining survivors in the group that was primed with HK B. pseudoma/lei 
pulsed DC and boosted with HK B. pseudoma/lei in MPL + TOM did have evidence of 
B. pseudoma/lei in the spleen samples, this was limited «10 cfu). Taken with the 
inability to culture organisms from one of the survivors and the fact that no 
hepatosplenomegaly was present or abscesses apparent on any organs suggests effective 
bacterial clearance was in progress and had the experiment been extended, complete 
clearance may have been achieved. 
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Immunisation group 
Brain 
Pulsed DC I / B.ps2 
Pulsed DC / B.ps 
Pulsed DC / B.ps 
B.ps / B.ps 
1 DC pulsed with HK B. pseudomal/ei 
2 HK B. pseudomal/ei in MPL + TDM 
o 
o 
o 
o 
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Number of colony forming units counted 
Liver 
o 
o 
o 
o 
Spleen 
<10 
o 
<10 
o 
Blood 
o 
o 
o 
o 
Table 3.1 Assessment of remaining bacterial burden in challenge survivors 
Challenge survivors were assessed for B. pseudomallei present in tissues (brain, liver, spleen and blood). 
One mouse from each of the groups with survivors had no B. pseudomallei present in any of the tissues 
cultured. While the remaining survivors in the group primed with HK B. pseudomal/ei pulsed DC and 
boosted with HK B. pseudomallei in MPL + TDM did have evidence of B. pseudomallei in the spleen 
samples, this was limited. 
3.4.2.2 Intranasal dosed groups 
Mice immunised with either HK B. pseudomallei pulsed DC via the IN route, HK B. 
pseudomallei delivered in MPL + TOM via the IM route or a combination of the two 
fonnulations were challenged with virulent B. pseudomallei (NCTC 4845) via the intra-
peritoneal (JP) route (Figure 3.25). Again due to the inability to quantify challenge 
doses prior to challenge, mice were challenged with 8.8 x 104 cfu (271 LOso) rather than 
the target challenge dose of 1 x 104 cfu. Animals were closely observed for 35 days 
following challenge, during which time any animals showing signs of severe illness 
were humanely culled. 
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All the naive mice and those primed and boosted with HK B. pseudomallei pulsed DC 
died by day 9 post challenge. No delayed time to death or survival was observed in the 
group that had been primed with HK B. pseudomallei pulsed DC and boosted with HK 
B. pseudomallei delivered in MPL + TOM. The group primed and boosted with HK B. 
pseudomallei in MPL + TDM again demonstrated a 20% survival rate, which was found 
to be statistically significant (p<0.05) when compared to the naIve controls. 
3.5 Elucidation of the protective immune response 
Data so far had indicated a possible role for antibody in protection against B. 
pseudomallei, which due to its intracellular nature, was unexpected. Thus the protective 
immune response (following immunisation with HK B. pseudomallei pulsed DC and 
HK B. pseudomallei in MPL + TOM) demonstrated by the challenge experiments was 
further investigated. Groups of 18 mice were immunised with each of the different 
immunisation combinations, HK B. pseudomallei pulsed DC were delivered via the ID 
route and HK B. pseudomallei in MPL + TOM via the IM route as previous. At weekly 
intervals following the day 0 immunisation two mice from each group were cardiac 
punctured while under terminal anaesthesia (halothane) and their spleens excised. CD 
4+ and CD 8+ T cells were then purified and assayed for memory phenotype as 
described in 2.4.3.2. Sera were assayed for anti-B. pseudomallei antibodies, which were 
also isotyped. 
3.5.1 Magnet assisted isolation of T cells from murine spleen 
Magnetic separation of CD4+ and CD8+ T cells from murine spleen was performed in 
accordance with the manufacturer's instructions. Isolation was performed on a single 
column, which afforded around 91 % (± 4.7%) purity in the isolated cell type, as 
68 
Chapter 3 - Results 
determined by flow cytometry analysis (data not shown as consistent with manufacturer 
reported purity). 
3.5.2 CD 4+ I CD 8+ memory T cell responses to immunisation 
Figure 3.26 shows the CD 4+ T cell memory response at weekly intervals during the 
immunisation regimen. Immunisation with a priming dose (Day 0) of either HK B. 
pseudomallei pulsed DC or HK B. pseudomallei in MPL + TOM produced a significant 
increase in the CD 4+ memory T cell recall response (p<0.05) compared to the nai've 
controls. Prime immunisation with pulsed DC produced a significantly greater (p<O.O 1) 
recall response than that produced following immunisation with HK B. pseudomallei in 
MPL + TOM. In both cases the response peaked 2 to 3 weeks following the priming 
dose and then returned to naive levels by day 30 of the immunisation regimen. After 
administration of the booster doses (Day 28) the group primed and boosted with HK B. 
pseudomallei in MPL + TDM failed to respond to the boost dose, while the group 
primed and boosted with HK B. pseudo mallei pulsed DC did respond. Although this 
response was significantly greater (p<0.05) than that of the naive controls, it was not as 
pronounced as the recall response following the priming dose and had returned to naive 
levels by day 44. The group primed with HK B. pseudomallei pulsed DC and boosted 
with HK B. pseudomallei in MPL + TOM exhibited a lag phase for the first week after 
the booster immunisation during which time the recall response continued to drop. By 
day 44 the recall response had increased to approximately two-fold the levels achieved 
after the priming dose. This response was significantly greater than all the other test 
groups (p<O.O 1) and was also more prolonged, not returning to naiVe levels until day 
65. 
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CD 8+ T cell recall responses (Figure 3.27) also demonstrated a biphasic response to 
immunisation. Priming with HK B. pseudomallei pulsed DC resulted in a peak recall 
response by day 16, which was greater than that of the other test groups (p<O.05), and 
had returned to naive levels by day 30. The group primed with HK B. pseudomallei in 
MPL + TDM did not produce a recall response greater than that observed for the na'ive 
controls (p>O.05). Following the booster dose, recall responses greater than the naIve 
controls were observed from the group primed and boosted with HK B. pseudomallei 
pulsed DC (p<O.05). No statistically significant increase was noted for the group 
primed and boosted with HK B. pseudo mallei in MPL + TOM (p>O.05). The group 
primed and boosted with HK B. pseudomallei pulsed DC also showed an increased CD 
8+ T cell recall response out to day 44 of the immunisation regimen (p<0.05). The 
group primed with HK B. pseudomallei pulsed DC and boosted with HK B. 
pseudomallei in MPL + TOM again exhibited a lag phase for the first week following 
booster immunisation. This lag phase, gave way to a significantly increased recall 
response (p<O.05), which continued to increase out to day 58, the increase between days 
58 and 65 was not found to be significant (p>O.05). 
3.5.3 Antibody responses to immunisation 
3.5.3.1 Total IgG responses 
Total IgG responses were determined at weekly intervals during the immunisation 
regimen and are shown in Figure 3.28. Priming doses for all groups did not stimulate 
any significant antibody production above that of naive levels (p>O.05). Whilst this was 
expected for DC immunisation, it was unusual following immunisation with HK B. 
pseudomallei in MPL + TOM, which previous experiments had shown was very 
effective at stimulating antibody production (figure 3.20). Following booster 
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immunisation, the group primed and boosted with HK B. pseudomallei pulsed DC, as 
expected, produced no antibody above naiVe levels. The other two immunisation 
groups showed a steady increase in total IgG over the next 5 weeks. Both these 
responses were found to be significantly greater compared to the naiVe controls 
(p<0.05) although the group primed and boosted with HK B. pseudomallei in MPL + 
TDM had significantly less total IgG by week five post-booster immunisation than in 
previous experiments. 
3.5.3.2 IgG subclass responses 
In the naiVe group very little anti-B. pseudomallei antibody was detected for any of the 
isotypes (<200 ng mL-1), especially IgG 1 where concentrations were below detection 
limits (figure 3.29). Mice primed and boosted with HK B. pseudomallei pulsed DC also 
failed to mount an anti-B. pseudomallei antibody response for any of the isotypes tested 
(p>0.05), compared to the naive controls. Mice primed and boosted with HK B. 
pseudomallei in MPL + TOM showed significantly greater concentrations of IgG2a, 2b 
and 3 than the naiVe controls (p<0.05) (figure 3.29). Greater concentrations of IgG2a 
and 2b were also noted compared to the group primed with HK B. pseudomallei pulsed 
OC and boosted with HK B. pseudomallei in MPL + TOM (p<0.05). This latter group 
was however noted as having significantly greater IgG 1 concentrations compared to all 
other test groups (p<O.OOI) (figure 3.29). 
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Figure 3.1 Phase contrast images of dendritic cell culture 
a) Phase contrast image of proliferating balls of dendritic cells (x20 magnification) indicated by the white arrows. Balls of proliferating cells 
b) 
-...I 
N 
were observed after four days of the culture of bone marrow progenitor cells in the presence of GM-CSF and TNF-a. 
Phase contrast image (x40 magnification) of a proliferating ball of dendritic cells. Q 
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Figure 3.2 Forward and side scatter profile of purified dendritic cells 
Flow cytometry forward scatter (FSC-H) / side scatter (SSC-H) profile of dendritic cells 
following purification from culture using metrizamide density centrifugation gradient. 
Dendritic cells (gated in red) exhibit a typical high FSC-H / SSC-H profile and typically 
constituted greater than 80% of the culture population. 
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Figure 3.3 Immature dendritic cell phenotype 
Phenotype of immature dendritic cells obtained after four days of culture in the 
presence of GM-CSF and TNF-a, and purified on a metrizarnide density gradient: MHC 
CD 54+ and CD 40+. Blue open curve shows negative control, purple closed curve the 
stained cell population. Expression pattern was consistently observed in five separate 
experiments. 
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Figure 3.4 Comparison of the proportion of mature dendritic cells following culture in different cytokine environments 
Percentage of mature dendritic cells occurring under each of the three cytokine culture conditions: a) GM-CSF & TNF-a (24.45%); b) GMCSF, 
TNF-a & IL-12 (23.91%); c) GM-CSF, TNF-a & lL-4 (31.05%). The mature population was determined on the basis of high MHC class II 
expression, which is considered characteristic of a mature dendritic cell phenotype. This experiment was repeated five times and no significant ("') 
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Figure 3.5 Maturation of GM·CSF I TNF·a, cultured dendritic cells following inflammatory stimuli 
Maturation was assessed in terms of the increase in percentage of mature cells, depicted by high expression of MHC class 11 (blue), CD 80 (red), 
CD 86 (yellow) and CD 54 (turquoise), as compared to control unstimulated dendritic cells. 
a) Maturation fo llowing exposure to 50 ng mL-1 TNF-a resul ted in a marked increase in all markers, except CD 80, wi th the greatest 
expression observed 48 hours after exposure. 
b) Maturation following exposure to 10 ng rnL- 1 LPS stimulated a marked increase in all markers. Maturation resulting from LPS exposure \) 
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occurred more rapidly and to a greater extent than that st imulated by exposure to TNF-a. 
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Figure 3.6 Maturation of GM-CSF / TNF-(l / IL-4 cultured dendritic cells following inflammatory stimuli 
Maturation was assessed in terms of the increase in percentage of mature cells, depicted by high expression of MHC class IT (blue), CD 80 (red), 
CD 86 (yellow) and CD 54 (turquoise), as compared to control unstimulated dendritic cells. 
a) Maturation following exposure to 50 ng mL-1 TNF-a resulted in a marked increase in MHC class 11, CD 86 and CD 54, with the greatest 
expression observed 48 hours after exposure. 
b) Maturation following exposure to 10 ng mLl LPS stimulated a marked increase in all markers. Maturation resulting from LPS exposure 
occurred more rapidly and to a greater extent than that stimulated by exposure to TNF-a, peaking after 24 hours. 
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Figure 3.7 Maturation of GM-CSF / TNF -a./ IL-12 cultured dendritic cells following inflammatory stimuli 
Maturation was assessed in terms of the increase in percentage of mature cells, depicted by high expression of MHC class II (blue), CD 80 (red), 
CD 86 (yellow) and CD 54 (turquoise), as compared to control unstimulated dendritic cell s. 
a) Maturation fo llowing exposure to 50 ng mL-1 TNF-a resul ted in an increase in MHC class n, CD 86 and CD 54 by 24 hours. Further 
culture, however, was associated with decreased expression by 48 hours. 
b) Maturation fo llowing exposure to 10 ng mL·1 LPS stimulated a marked increase in all markers. Maturation resulting from LPS exposure 
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occurred more rapidly and to a greater extent than that stimulated by exposure to TNF-a, peaking after 48 hours. 9 
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Figure 3.8 Cytokine secretion by GM-CSF I TNF -Cl cultured dendritic cells following inflammatory stimuli 
Cytokine secretion from DC cultured in the presence of GM-CSF and TNF-a.. Cytokines assayed were IFN-y (blue), lL-5 (red), IL-2 (turquoise) 
and 1L-1O (orange bar). 1L-4, LL-12p70 and 1L-6 were also assayed but no increase in secretion was noted. All concentrations are normalised 
against control unstimulated DC. Error bars signify +SEM, which is calculated from the mean of three replicates. 
a) Cytokine secretion following exposure to 50 ng mL- 1 TNF-a was seen to increase for all cytokines assayed by 24 hours, of which the 
b) 
-..J 
\D 
increase in IL-1O was found to be significant (p<0.05). 1L-2 was not detectable by 48 hours post-exosure. 
Cytokine secretion following exposure to 10 Ilg mL- 1 LPS demonstrated the same pattern as for TNF-a exposure with approximately a two-
fold increase in concentration. Again IL-1O was found to be significantly greater (p<0.05) compared to control secretion levels. 
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Cytokine secretion by GM-CSF / TNF -a. / IL-4 cultured dendritic cells following inflammatory stimuli 
IFN-g 
ll.r 10 
Cytokine secretion from DC cultured in the presence of GM-CSF, TNF-a and IL-4. Cytokines assayed were IFN-y (blue), IL-5 (red), IL-2 
(turquoise) and IL-1O (orange bar). IL-4, IL-12p70 and IL-6 were also assayed but no increase in secretion was noted. All concentrations are 
normalised against control unstimulated DC. Error bars signify +SEM, which is calculated from the mean of three replicates. 
a) Cytokine secretion following exposure to 50 ng mL-1 TNF-a was too variable to be able to discern any significant patterns. 
b) Cytokine secretion following exposure to 10 f..lg mL- ' LPS was seen to significantly increase for both lFN-y (p<0.05) and IL-lO (p<0.05) 
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Figure 3.10 Cytokine secretion by GM-CSF / TNF-a./ IL-12 cultured dendritic cells following inflammatory stimuli 
Cytokine secretion from DC cultured in the presence of GM-CSF, TNF-a and IL-12. Cytokines assayed were IFN-y (blue), lL-5 (red), lL-2 
(turquoise) and IL-lO (orange bar). IL-4, IL-12p70 and IL-6 were also assayed but no increase in secretion was noted. All concentrations are 
normalised against control unstimulated DC. Error bars signify +SEM, which is calculated from the mean of three replicates. 
a) Cytokine secretion following exposure to 50 ng mL-1 TNF-a was too variable to be able to discern any significant patterns. 
b) Cytokine secretion following exposure to 10 J.1g mL-1 LPS was seen to significantly increase for both IFN-y (p<0.05) and IL- lO (p<O.Ol) 
compared to control unstimulated DC. 
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Figure 3.11 Dendritic cell maturation following exposure to HK R pseudomallei 
Dendritic cell maturation following exposure to heat ki lled B. pseudomallei. Cell 
surface express ion of MHC class II (a) and CD 80 (b) was noted to peak 12 hours post 
exposure (purple closed curve). Blue open curve depicts expression at 0 hours. 
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Figure 3.12 Dendritic cell maturation following exposure to HK B. pseudomallei 
Dendri tic cell maturation fo llowing exposure to heat ki lled B. pseudomaLlei. Cell 
surface expression of CD 86 (a) and CD 205 (b) was noted to peak 12 hours post 
exposure (purple closed curve). Blue open curve depicts expression at 0 hours. 
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Figure 3.13 Percentage of marker bright dendritic cells following exposure to HK B. pseudomallei 
96 
96 
Continued culture of the DC in the presence of HK B. pseudomaUei resulted in a sustained mature population of cells. This population, identified 
by the expression of high levels of MHC class n, CD 80, CD 86 and CD 205, was noted to persist over the 96 hours of culture. Error bars signify 
+SEM, calculated from the mean of five experiments 
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Figure 3.14 Dendritic cell morphological changes following exposure to HK B. pseudomaUei 
Changes in DC morphology following exposure to 1 x 104 cfu HK B. pseudomallei per 2 x 106 cells. Elongation of the DC is apparent by 3 hours 
with long dendritic like projections becoming clearly visible by 18 hours. 
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Figure 3.15 Dendritic cell cytokine secretion following exposure to HK B. 
pseudo mallei 
Dendritic cell cytokine secretion, 12 hours after exposure to HK B. pseudomallei. 
Increases in lFN-y, IL-S and IL-2 secretion were noted together with significant 
increases in IL-12p70 (p<O.05) and IL-lO (p<O.05) secretion. Error bars signify +SEM, 
which is calculated from the mean of three replicates. 
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Figure 3.16 Dendritic cell IL-6 secretion following exposure to HK B. 
pseudo mallei 
Dendritic cell secretion of IL-6, 12 hours after exposure to HK B. pseudomallei. A 
significant increase in IL-6 (p<O.O I) secretion was observed compared to control 
unstimulated DC. Error bars signify +SEM, which is calculated from the mean of three 
replicates. 
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Figure 3.17 NaYve Iymphocyte proliferation to HK B. pseudomallei pulsed 
dendritic cells 
For all concentrations and ratios investigated, proliferation was significantly greater 
than that of the negative control (p<O.OOl). A DC to lymphocyte ratio of 1 to 10 
resulted in the greatest level of proliferation (p<0.05). The optimum concentration was 
determined as 1 x 104 cfu mL-1 (p<0.05) and the greatest level of proliferation occurred 
between two and four days of co-culture (p<O.05). Blue bars represent the DC to 
Iymphocyte ratio 1 to 10, red bars 1 to 100 and yellow bars I to 1000. Turquoise bars 
represent the lymphocyte only control. Error bars signify +SEM, which is calculated 
from the mean of five replicates from pooled lymphocytes from five separate spleens. 
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Figure 3.18 Recall memory responses following immunisation (priming) with 
HK B. pseudo mallei pulsed dendritic cells or HK B. pseudomallei 
delivered in adjuvant 
Memory responses four weeks after the priming dose with HK B. pseudomallei in MPL 
+ TDM peaked after six days of culture at which point responses were significantly 
greater (p<O.05) than the level of proliferation seen for the naIve controls. 
Immunisation with a priming dose of HK B. pseudomallei pulsed DC however, 
stimulated a significantly greater memory response (p<O.OO I) than that observed 
following immunisation with HK B. pseudomallei in MPL + TDM, which was also 
much more rapid peaking after four days of culture. Error bars signify +SEM, which is 
calculated from the mean of five replicates from pooled lymphocytes from five separate 
spleens. 
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Figure 3.19 Recall memory responses following immunisation (booster) with HK 
B. pseudomallei pulsed dendritic cells or HK B. pseudo mallei 
delivered in adjuvant 
Memory responses five weeks after the booster dose were noted to be more rapid for 
both the test groups. Proliferation for the group primed and boosted with HK B. 
pseudomallei in MPL + TOM was greater than that seen after the priming dose and also 
peaked a day earlier after five days of culture. While no significant difference was 
observed in the level of memory proliferation seen in the group primed and boosted 
with HK B. pseudomallei pulsed DC, proliferation was noted to peak a day earlier after 
the booster dose after three days of culture demonstrating a faster recall response. Error 
bars signify +SEM, which is calculated from the mean of five replicates from pooled 
lymphocytes from five separate spleens. 
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Figure 3.20 Humoral responses following immunisation with HK B. pseudomallei 
pulsed dendritic cells or HK B. pseudomallei delivered in adjuvant 
Immunisation with HK B. pseudomallei delivered in MPL + TDM (IM) induced a 
strong anti-B. pseudomallei antibody response, which was significantly greater than 
both the HK B. pseudomallei pulsed DC immunised (ID) and na"ive groups (p<O.05) 
after a single immunisation. Booster immunisation at day 28 augmented the response to 
approximately four-fold the levels achieved after the priming dose. No antibody 
production was observed following immunisation with HK B. pseudomallei pulsed DC 
above that seen in the nai"ve group at either time point. Error bars signify +SEM, which 
is calculated from the mean of four replicates from sera from five test subjects. 
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Figure 3.21 Cellular and humoral responses following intradermal immunisation 
Following ID immunisation, groups primed with HK B. pseudomallei pulsed DC 
displayed a significantly greater cellular recall response (p<O.OO I) than immunisation 
with HK B. pseudomallei in MPL + TDM (IM). Antibody responses however, for the 
group primed and boosted with HK B. pseudomallei in MPL + TDM were significantly 
greater than those observed in the groups that received HK B. pseudomallei pulsed DC 
(p<O.05) as one or both immunisation doses. Substitution of the booster DC dose with 
HK B. pseudomaUei in MPL + TDM resulted in a significant increase in antibody 
production (p<O.05) as compared to the group that received two doses of HK B. 
pseudomaUei pulsed DC. No significant change in the cellular recall response was 
observed as a result of this substitution. Error bars signify +SEM, which is calculated 
from the mean of five replicates from pooled lymphocytes from five separate spleens. 
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Figure 3.22 Cellular and humoral responses following intranasal immunisation 
Following IN immunisation, groups primed with HK B. pseudomallei pulsed OC 
displayed a significantly greater cellular recall response (p<O.OO I) than immunisation 
with HK B. pseudomallei in MPL + TOM (IM). Antibody responses however, for the 
group primed and boosted with HK B. pseudomallei in MPL + TOM were significantly 
greater than those observed in the groups that received HK B. pseudomallei pulsed OC 
(p<O.05) as one or both immunisation doses. 
For the IN dosed groups, substitution of the day 28 HK B. pseudomallei pulsed DC dose 
with a dose of HK B. pseudomallei delivered in MPL + TOM afforded no significant 
changes in either the cellular or antibody responses observed. Error bars signify +SEM, 
which is calculated from the mean of five replicates from pooled Iymphocytes from five 
separate spleens. 
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Mortality 
Dilution Died Survived Ratio Percentage 
1 x 10-3 5 0 5/5 100 
1 x 10-4 5 0 5/5 100 
1 x 10-5 4 1 4/5 80 
1 x 10-6 0 5 0/5 0 
1 x 10-7 0 5 0/5 0 
Figure 3.23 LDso experiment survival curve and mortality data table 
All test subjects from the groups challenged with 7.7 x 104 cfu and 7.7 x 103 cfu B. 
pseudomallei (NCTC 4845) died by days 12 and 28 respectively. The 7.7 x 102 cfu 
challenged group exhibited a 20 % survival rate while the remaining two groups 
challenged with 77 or 7.7 cfu both showed 100% survival. The mortality data table 
shows the doses and dilutions for each test group together with the mortality data 
allowing calculation of the LDso using the method of Reed and Muench (169). 
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Figure 3.24 Survival curve for intradermal immunised groups 
All naIve mice died by day 10 post challenge. All mice primed and boosted with HK B. 
pseudomallei pulsed DC died by day 16 post challenge. The group primed and boosted 
with HK B. pseudomallei in MPL + TDM displayed a significantly delayed time to 
death and 20% survival rate (p<0.OO5) compared to the naIve controls. The final group 
primed with HK B. pseudomallei pulsed DC and then boosted with HK B. pseudomallei 
in MPL + TDM displayed a significant delay in time to death and a 60% survival rate 
(p<0.OO5) compared to the naIve controls. In addition, a significant increase in time to 
death and survival rate was noted (p<0.005) for this last group when compared to the 
group that was primed and boosted with HK B. pseudomallei pulsed DC. 
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Figure 3.25 Survival curve for intranasal immunised groups 
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All the naIve mice and those primed and boosted with HK B. pseudomallei pulsed OC 
died by day 9 post challenge. No delayed time to death or survival was observed in the 
group that had been primed with HK B. pseudomallei pulsed OC and boosted with HK 
B. pseudomallei delivered in MPL + TOM. The group primed and boosted with HK B. 
pseudomallei in MPL + TOM again demonstrated a 20% survival rate, which was found 
to be statistically significant (p<0.05) when compared to the naIve controls. 
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Figure 3.26 Splenic CD 4+ T cell recall responses following prime and boost 
immunisations 
65 
Priming with either HK B. pseudomaUei pulsed DC or HK B. pseudomallei in MPL + 
TDM produced a significant increase in the CD 4+ memory T cell recall response 
(p<O.05) compared to the naIve controls. Immunisation with HK B. pseudomaLlei 
pulsed DC produced a significantly greater (p<O.O 1) recall response than immunisation 
with HK B. pseudomaLlei in MPL + TDM. After booster immunisation the greatest 
recall response was noted for the group primed with HK B. pseudomallei pulsed DC 
and boosted with HK B. pseudomallei in MPL + TDM (p<O.Ol). Error bars signify 
±SEM, which is calculated from the mean of four replicates from the pooled T cells 
from two test subjects. 
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Figure 3.27 Splenic CD 8+ T cell recall responses following prime and boost 
immunisations 
65 
Immunisation with HK B. pseudomaUei pulsed DC resulted in the greatest recall 
response following priming (p<O.05). Following booster immunisation, recall 
responses greater than the naIve controls were observed from the group primed and 
boosted with HK B. pseudomallei pulsed DC (p<O.05). This immunisation group also 
showed a trend of increased CD 8+ T cell recall responses out to day 44 (p<O.05). The 
group primed with HK B. pseudomallei pulsed DC and boosted with HK B. 
pseudomallei in MPL + TDM showed a significantly greater response than all other 
groups (p<O.05). Error bars signify ±SEM, which is calculated from the mean of four 
replicates from the pooled T cells from two test subjects. 
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Figure 3.28 Total IgG responses following prime and boost immunisations 
65 
Prime doses for all groups did not stimulate any significant antibody production above 
that of naIve levels. Whilst this was expected for DC immunisation, it was unusual 
following immunisation with HK B. pseudomallei in adjuvant, which previous 
experiments had shown was very effective at stimulating antibody production. 
Following boost immunisation the group receiving two doses of pulsed DC, as 
expected, produced no antibody above naIve levels. The other two immunisation 
groups, show a steady increase in total IgG over the next 5 weeks. Both these responses 
were found to be significantly greater compared to the naIve controls although the 
group administered two doses of HK B. pseudomallei in adjuvant had significantly less 
total IgG than in previous experiments. Error bars signify ±SEM, which is calculated 
from the mean of four replicates from the sera from two test subjects. 
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Figure 3.29 IgG subclasses following different immunisation regimen 
Mice primed and boosted with HK B. pseudomaLlei pulsed DC failed to mount an 
antibody response greater than that seen for the naIve controls. Mice primed and 
boosted with HK B. pseudomaLlei in MPL + TOM showed significantly greater 
concentrations of IgG2a, 2b and 3 than the na'ive controls (p<O.05). Greater 
concentrations of IgG2a and 2b were also noted compared to the group primed with HK 
B. pseudomallei pulsed DC and boosted with HK B. pseudomaLlei in MPL + TOM 
(p<O.05). This latter group was however noted as having significantly greater JgG 1 
concentrations compared to all other groups (p<O.OOl). Error bars signify +SEM, 
which is calculated from the mean of four replicates from the sera from two test 
subjects. 
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4.1 Introduction 
The need for an efficacious vaccine against B. pseudomallei is clear, particularly in the 
context of the increasing antibiotic resistance of the organism (35,48,190). This study 
addresses a particular approach to vaccination, utilising dendritic cells as a vaccine 
delivery vehicle, and has also partially elucidated the immune response required to 
achieve protection against B. pseudomallei infection. 
4.2 Dendritic cell culture, phenotype and maturation 
The isolation and culture of a wide range of DC subtypes has been reported, which 
provides evidence of the heterogeneity of the DC population. The data from this study 
describes the generation of high yield, high purity cultures of DC in a relatively short 
time scale. DC produced in this culture system, when the culture medium was 
supplemented with GM-CSF and TNF-<l, were phenotypically myeloid. The addition 
of either IL-4 or IL-12 to the culture, which has previously been shown to have a 
polarising effect on DC (92), did not result in any notable phenotypic changes to the DC 
produced from this culture system. Cytokine secretion patterns did vary however, under 
the different cytokine environments. The addition of IL-4 to the culture was associated 
with an increase in IFN-y secretion following LPS stimulation, compared to the GT 
cultured DC (p<O.05), suggesting a homeostatic response from the DC popUlation in 
response to the high levels of IL-4, which would have produced a Th2 cytokine bias. 
The presence ofIL-12 in the culture however, did not stimulate an opposite homeostatic 
response, which might have been expected. The most notable difference from the group 
cultured in the presence oflL-12 was a significant increase in IL-IO secretion following 
LPS stimulation, compared to the GT cultured DC (p<O.O 1). IL-IO is a potent anti-
inflammatory factor that has been shown to inhibit macrophage activation resulting in 
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the reduced expression of pro-inflammatory cytokines such as TNF-a, IL-I, IL-6, IL-12 
and GM-CSF (52,69). Thus the presence of high concentrations oflL-12 in the culture 
might have stimulated the production ofIL-IO in response to the artificial inflammatory 
environment created by IL-12 in the culture medium. The presence of TNF-a in the 
culture would also likely have compounded this effect, and may account for the IL-IO 
secretion seen in all three culture environments. 
Maturation responses, assessed through increases in the cell surface markers MBC class 
11, CD 80, CD 86 and CD 54, revealed similar patterns of expression during the 48 
hours following exposure to inflammatory stimuli. However the varying effect of 
adding either IL-4 or IL-12 to the culture meant that only GM-CSF and TNF-a were 
used as a supplement to the culture for further experimentation. 
4.3 In vitro responses 
Further work then assessed the response ofthe dendritic cells following exposure to ilK 
B. pseudomallei. The time-to-maturation response, compared to LPS or TNF-a 
exposure, was quicker following exposure to HK B. pseudomallei. There are a number 
of potential explanations for this; the most likely of which is concentration. Although 
the number of bacteria added to the DC culture was standardised, molar comparisons 
were not made between LPS concentrations from the HK B. pseudomallei and that of 
the purified LPS, so that the concentration of LPS added when using HK B. 
pseudomallei may have been optimum for inducing maturation. In addition, the 
presence of other inflammatory and/or maturation-inducing bacterial products, when 
HK B. pseudomallei was added to the culture, are also likely to have had a stimulatory 
effect on maturation. In addition to quicker maturation, the high expression of MIIC 
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class 11, CD 80, CD 86 and CD 205 was maintained over 96-hours of in vitro culture 
with no further stimulation (Figure 3.13). 
Cytokine secretion from the DC following exposure to HK B. pseudomallei 
demonstrated a mixed cytokine profile (Figures 3.15 and 3.16). No IL-4 secretion was 
observed (consistent with the literature, which suggests that professional APC's do not 
secrete IL-4 (59» and changes in IL-2, IL-5 and IFN-y secretion were not statistically 
significant. Significant increases in IL-12p70 (p<0.05), IL-lO (p<O.05) and IL-6 
(p<O.O 1) were however noted. 
These three cytokines play contrasting roles in the generation of immune responses. IL-
12 has been shown to play a central role in the generation of type 1 T helper cell 
responses and cell-mediated immunity (77,161); stimulating the proliferation of 
activated T and NK cells (76,117,197,227), enhancing the lytic activity ofNK cells and 
cytotoxic T lymphocytes (36,117,227) and inducing the production of IFN-y by both T 
and NK cells (31,117,197,227). 
In contrast, IL-6 is more often associated with Th2 T cell development and the 
stimulation of antibody mediated immunity (149), inducing the expression of the IL-4 
gene during T cell activation (59). Produced by a number of cell types including DC 
(59) in response to inflammatory stimuli, IL-6 also induces the synthesis of acute phase 
proteins in heptocytes, the terminal differentiation of B cells to plasma cells, 
differentiation of monocytes to macrophages and the growth of haematopoietic stem 
cells (93). 
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IL-I0 is a pleiotropic cytokine that has an important role in regulating the immune 
response (226) and is produced by a range of cells including DC (68,144). The main 
biological functions of IL-l 0 are to limit and terminate inflammatory responses, block 
pro-inflammatory cytokine secretion and regulate the differentiation of T cells, B cells, 
NK cells and mast cells (226). 
The conflicting roles of these cytokines meant that few conclusions could be drawn 
regarding likely in vivo immune responses on the basis of the in vitro data alone. Of 
initial concern however, in terms of attempting to generate primary immune responses 
in vivo was the high level of IL-l 0 secretion noted from the DC cultures. IL-I0 has 
been shown to inhibit the production of IL-2, IFN-y, IL-4 and IL-5 (53,182,205) by CD 
4+ T cells, stifling T cell responses. It has also been shown to suppress APC activation 
and antigen presentation by inhibiting the expression of MHC class 11, CD 80 and CD 
86 on macrophages and dendritic cells (32,60). Although the maturation data (Figures 
3.11 to 3.13) had suggested that such an effect on the maturation of the DC was not 
present, it was important to assess the ability of HK B. pseudomallei pulsed DC to 
generate primary immune responses. 
To achieve this aim DC, pulsed with varying concentrations of HK B. pseudomallei, 
were incubated with T lymphocytes in different ratios. This enabled not only an 
assessment of their ability to generate primary immune responses, but also an 
opportunity to optimise conditions for later in vivo work. Statistically, optimum in vitro 
proliferation was observed at the relatively low pulsing concentration of 1 x 104 cfu mL" 
I of HK B. pseudomallei. However, actual differences between the peak proliferation 
observed at each of the concentrations investigated were relatively small, suggesting 
that the observed statistical difference might not correlate with an in vivo biological 
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difference. Repeat experiments and the investigation of pulsing doses below 104 cfu 
mL-1, which were unable to be carried out due to project time constraints, may have 
better clarified any such effect. What was evident from this data was that the DC were 
generating primary immune responses. This was inferred from the fact that the 
unpulsed DC failed to generate equivalent responses to the pulsed DC, demonstrating 
the lack of a non-specific proliferative response from the DC alone. Later experiments 
(e.g. Figure 3.18) also showed that the addition of HK B. pseudomallei to nai've 
lymphocytes, although stimulatory, was not as effective at inducing Iymphocyte 
proliferation as HK B. pseudomallei pulsed DC. Thus, taken together these data 
indicate that the primary responses seen were B. pseudomallei specific. This was of 
particular importance in the context of B. pseudomallei infection, as an intracellular 
pathogen, and also when considering the suitability of DC as a vaccine system, which 
could demonstrably produce an effective CMI response. 
4.4 In vivo responses 
Investigation of the in vivo immune responses following immunisation with HK B. 
pseudomallei pulsed DC or B. pseudomallei in MPL + TOM, demonstrated a superior T 
cell recall response (p<O.OOI) after immunisation with HK B. pseudomallei pulsed DC 
following both prime and booster immunisations. Investigation of the humoral 
responses to immunisation demonstrated a significantly lesser anti-B. pseudomallei 
antibody response from the group immunised with HK B. pseudoma/lei pulsed DC, 
which failed to generate any antibody above nai've levels, compared to the group 
immunised with HK B pseudomallei in MPL + TOM (p<O.05). Due to the lack of 
available literature on the protective immune response requirements for B. pseudomallei 
infection, the immunisation regimen was further altered in an attempt to generate a 
more balanced immune response for better comparison. Hence the two vaccine 
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formulations were combined to create a regimen of a priming (day 0) dose of HK B. 
pseudoma/lei pulsed DC followed by a booster (day 28) dose ofHK B. pseudomallei in 
MPL + TDM. The effect of delivering the HK B. pseudomallei pulsed DC via the IN 
instead of the ID route was also investigated. This immunisation group was originally 
intended for an aerosol challenge experiment, but laboratory equipment problems at the 
time of challenge prevented the experiment going ahead. As a result the immunised 
mice were challenged via the IP route to allow a comparison of the different routes of 
immunisation. Following ID immunisation of the HK B. pseudoma/lei pulsed DC and a 
booster immunisation with HK B. pseudoma/lei in MPL + TDM (IM), an increase in the 
concentration of circulating anti-B. pseudomallei antibody (p<0.05) compared to 
immunisation with two doses of HK B. pseudoma/lei pulsed DC was noted. The same 
combination of formulations, but utilising the IN route for delivery of the IlK B. 
pseudomallei pulsed DC, resulted in no such increase in humoral response (p>O.05), 
despite a CMI recall response that was equivalent to that noted following ID 
administration of the HK B. pseudomallei pulsed DC. The reasons for this difference 
have not been investigated here due to project monetary constraints, but are possibly 
due to the very different routes of administration between the prime and booster 
immunisations when the IN route was used. In vitro proliferation data demonstrated 
that both routes of immunisation (ID and IN) successfully primed cellular systemic 
immunity, but it is possible that IN administration of the HK B. pseudoma/lei pulsed 
DC may not have primed for systemic humoral immunity. It is difficult to speculate as 
to the exact reasons and mechanisms for the lack of humoral immunity following the 
booster dose of HK B. pseudoma/lei in MPL + TDM. Especially since exposure of 
APC to antigen in the lungs generally favours a humoral over a cellular response, due to 
the potential consequences to the host of damage to pulmonary tissues resulting from a 
strong cytotoxic response (128). It does however, highlight the importance of the route 
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of immunisation on the type of immune response that ensues and also the need for 
rational vaccine design. 
Challenge investigations using the different immunisation regimens suggested that 
antibody might play an important role in protection against B. pseudomallei infection. 
Following ID immunisation, the group receiving two doses of HK B. pseudomallei 
pulsed DC (ID) all died, despite a superior cell-mediated immune response (p<O.OOI). 
Whilst those receiving two doses of HK B. pseudomallei in MPL + TDM (lM) or the 
combined regimen, which both had increased antibody levels (p<0.05), exhibited 20% 
(p<0.005) and 60% (p<0.005) survival rates respectively. In addition, a significant 
increase in time to death and survival rate (p<0.005) was noted for the combined 
regimen when compared to the group that received two doses of HK B. pseudomallei 
pulsed DC only. Data from the IN administered groups also corroborated these results, 
since the group receiving two doses of HK B. pseudomallei in MPL + TDM again 
exhibited a 20% survival rate (p<O.05) while the group primed and boosted with HK B. 
pseudomal/ei pulsed DC via the IN route all died. In addition, the group primed with 
HK B. pseudomallei pulsed DC (IN) and boosted with HK B. pseudomallei in MPL + 
TDM, which failed to mount a significant humoral response, also all died. This data 
therefore supported passive protection studies (21,24,111), which have previously 
suggested that antibody might play a role in protection against B. pseudomallei, with 
high circulating antibody concentrations being correlated with survival in mice and rats. 
Assessment of the survivor's bacterial burden at day 35-post challenge demonstrated 
that bacteria could not be cultured from any of the tissue samples from one subject of 
both groups with survivors. While the remaining survivors did have evidence of a 
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bacterial burden, this was limited and only present in splenic tissues, suggesting the 
infection might have been completely cleared had the experiment been extended. 
4.5 Elucidation of the protective immune response 
Taken together, these data provided strong evidence of a role for both humoral and cell-
mediated immunity in protection against B. pseudomallei infection since although the 
presence of a significant anti-B. pseudo mallei antibody response (compared to naive 
controls) was correlated with survival, the presence of a superior CMI response 
improved survival rates from 20% to 60% (p<O.05). Thus the immune responses 
generated by the different immunisation regimens were further characterised in an 
attempt to determine the protective immune response. IN administration of the DC was 
not considered here since no protection was afforded using this delivery route. 
Characterisation of the CD 4+ and CD 8+ T cell recall responses over the nine weeks of 
the immunisation regimen demonstrated a stark difference in the immune response 
generated. Significantly greater T cell recall responses (both CD 4+ and CD 8) were 
noted following priming with HK B. pseudomallei pulsed DC (ID) and boosting with 
HK B. pseudomallei in MPL + TDM (IM). In addition, the CD 8+ T cell recall response 
was observed to improve over the nine weeks of the regimen unlike the other groups in 
which it had diminished to narve levels by two weeks post-boosting. This continued 
increase following this immunisation regimen resulted in a significantly greater CD 8+ 
T cell response at the point of challenge (day 65 of the immunisation regimen). It is 
particularly noteworthy that such an increase in CD 8+ T cell recall response was not 
observed in the group primed and boosted with HK B. pseudomallei pulsed DC. This 
suggested that the combination of priming with HK B. pseudomallei pulsed DC and 
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boosting with HK B. pseudomal/ei in MPL + TOM was required to generate such a 
response. 
Recent work by Bancroft and colleagues (88) has suggested that CD 8+ T cells may play 
little or no role in protection against B, pseudomal/ei infection in the mouse model of 
melioidosis. This is based on the observation that mice immunised with the 202 mutant 
of B. pseudomal/ei (8) and then challenged following ablation of CD 8+ T cells with 
monoclonal antibodies, showed no observable increase in morbidity or mortality. CD 
8+ T cells however, have been shown to contribute to rapid IFN-y production following 
B. pseudomal/ei infection (124), which would serve to improve innate host cell killing 
mechanisms, augmenting the cytotoxic effect. The rapid induction of IFN-y has also 
been shown to prevent acute B. pseudomallei infection (177). 
In contrast to the CD 8+ data, ablation of CD 4+ T cells during the 202 work showed 
that they were required for protection (88) as their removal significantly reduced the 
time-to-death in mice challenged with fully virulent B. pseudomal/ei. This suggests that 
the significantly improved CD 4+ T cell response, observed following immunisation 
with a combination of HK B. pseudomal/ei pulsed DC and HK B. pseudomal/ei in MPL 
+ TOM, might have contributed to the improved survival in this group. 
In addition to the role of CMI, the antibody data also provided some insight into the role 
of humoral immunity in protection against B. pseudomal/ei infection. Total IgO 
antibody responses increased as expected following booster immunisation in the groups 
receiving either two doses of HK B. pseudomallei in MPL + TOM or the group primed 
with HK B. pseudomallei pulsed DC and boosted with HK B. pseudomallei in MPL + 
TOM. Although increased anti-B. pseudomallei IgO titres were correlated with survival 
110 
Chapter 4 - Discussion and conclusions 
in the challenge experiments (Figure 3.24). there was a disparity· between the 
concentration of antibody observed and survival, in that the greatest survival was not 
observed from the group with the highest antibody concentration. The significantly 
improved cell-mediated response (particularly CD 4+ T cells) in the group immunised 
with a combination ofHK B. pseudomal/ei pulsed DC and HK B. pseudoma/lei in MPL 
+ TDM (Figure 3.21) may provide an explanation for this observation. However. 
further clarification of the role of antibody might have been gleaned from investigation 
ofthe IgG subclasses produced by immunisation and was therefore carried out. 
Analysis of the JgG subclasses revealed another stark difference between the group 
immunised with the combination regimen and the group immunised with two doses of 
HK B. pseudomallei in MPL + TDM. Despite the typically greater antibody response of 
the group receiving two doses of HK B. pseudomallei in MPL + TDM. it was found to 
be predominantly an JgG2a response with no detectable IgG 1. In contrast the group 
primed with HK B. pseudomallei pulsed DC and boosted with HK B. pseudomallei in 
MPL + TDM developed a predominantly IgG 1 response (p<O.05) although all the 
isotypes were present. In the mouse. the JgG2a and 2b isotypes are the only isotypes to 
activate complement although this is unlikely to be the mechanism of bacterial killing in 
the group immunised with two doses of HK B. pseudomallei in MPL + TDM. because 
of the resistance of B. pseudomal/ei to complement lysis (196). Opsonisation is 
however, likely to play a role and may facilitate improved uptake and killing by 
phagocytes, although this has not been formally demonstrated for B. pseudomallei. The 
reasons for the low survival rate observed following immunisation with only HK B. 
pseudomallei in MPL + TDM, are likely several-fold. Efficient opsonisation would 
require high antibody concentrations and the intracellular nature of B. pseudomallei 
infection would only provide a small window of opportunity for such a mechanism of 
III 
Chapter 4 - Discussion and conclusions 
bacterial clearance. Once intracellular, the lack of a significant cell-mediated response 
to augment the humoral response would also mean that effective bacterial killing and 
clearance would be stifled. 
JgOl, generated only following immunisation with a combination of IlK B. 
pseudomallei pulsed DC and HK B. pseudomallei in MPL + TOM, while also 
opsonising, is also the only isotype in mice to bind to the low affinity Fcy RH (CD 32). 
This receptor is the most widely distributed of the Fcy receptors (219) and is 
significantly more effective at inducing phagocytosis (61) than Fey RI (CD 64) and Rill 
(CD 16). Of particular importance with regard to Fcy RH, is its role in antibody 
dependent cellular cytotoxicity (AOCC). This process enables the killing of target cells 
in the absence of complement activation and CD 8+ cytotoxic T Iymphocyte activity. 
During AOCC, lysis occurs following specific contact between the Fcy RH on the 
effector cells and IgOI located on the target cells (63,167). Further more, ADCC 
occurs at antibody concentrations well below that required for complement lysis or 
efficient killing mediated by phagocyte uptake of opsonised bacteria (63). 
As discussed in section 1.2.2.2, cytokines secreted during T cell stimulation play a 
pivotal role in the type of immune response that ensues. Differences in the cytokine 
environment during T cell stimulation are also likely to have had an influencing role on 
the different IgO subclass profiles observed from each of the immunisation regimens. 
This could be either from the DC used as a delivery vector or from host DC, which have 
been shown to be the primary cell involved in antigen presentation following 
immunisation with protein in adjuvant (85). In vitro, DC pulsed with IlK B. 
pseudomallei demonstrated a mixed cytokine profile that did not appear to favour a 
particular type of immune response. By considering the in vivo responses to 
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immunisation however, it is possible to better understand how each of these cytokines 
potentially influenced the ensuing immune response. 
Following immunisation with two doses of HK B. pseudomallei in MPL + TOM, 
significant levels of anti-B. pseudomallei IgG antibody were noted, predominantly 
composed of the IgG2a subclass and with no detectable IgG 1. This suggests a 
dominant role for IL-12 (secreted following pulsing of the OC with HK B. 
pseudomallei, Figure 3.15) during immunisation with this regimen, which has been 
shown to decrease IgG I production and enhance the production of IgG2a (215). The 
high concentration of antibody produced however, also indicates the influence of IL-6 
and IL-IO (also secreted following pUlsing of the OC with HK B. pseudomallei, Figures 
3.16 and 3.15 respectively). IL-6 is involved in the terminal differentiation of B cells to 
plasma cells (93) and IL-to enhances B cell survival and is a co-factor for the 
proliferation of B cell precursors and mature B cells (226). Indeed IL-6 and IL-I 0 have 
been shown to be essential for the production ofIgG and other isotypes by B cells (25). 
Subclass switching to IgGI, as observed following immunisation with a combination of 
HK B. pseudomallei pulsed DC and HK B. pseudomallei in MPL + TOM, occurs 
predominantly under the control ofIL-4 (149). Thus IL-6 is again essential since APC 
do not produce IL-4, but rather IL-6, which then stimulates the secretion of IL-4 by 
activated CD 4+ T cells (59). IL-to has also been shown to have an effect on isotype 
switching (25) and in addition increases the expression of Fcy RlI, a function that has 
been correlated with improved AOCC (209). In terms of the T cell response observed 
from immunisation with the combination regimen, IL-IO has been shown to have 
stimulatory effects on CO 8+ T cells, inducing their recruitment, cytotoxic activity and 
proliferation (82,179). These data suggest this cytokine might have been central to the 
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in vivo response that developed from this regimen, allowing the induction of a strong 
CD 8+ T cell proliferative response and isotype switching to JgG 1. 
These functions ofIL-I0 do not however, negate a role for IL-I2, which as previously 
mentioned is also pivotal in stimulating the proliferation of activated T cells 
(76,117,197,227) and in enhancing the lytic activity of cytotoxic T lymphocytes 
(36,117,227). Both these functions also suggest a possible role for this cytokine in the 
immune response generated by immunisation with the combination regimen. 
Consideration of immune regulatory functions of each of these cytokines suggests that 
they are each equally likely to have played a role in the developing immune response. 
It is unclear from this study, the precise effects of the cytokines secreted by the DC in 
vitro and further in vivo work is required to properly elucidate the role of the cytokine 
milieu post immunisation and post challenge. 
4.6 Conclusions 
The complexities of B. pseudomallei infection, coupled with its plethora of immune 
evasion strategies have so far eluded successful prophylaxis. Recent work is now 
beginning to shed light on the type of immune response required for protection against 
infection (8,88,124). 
The data presented here suggest that the immune response needed for protection against 
B. pseudomallei infection is likely to require strong humoral responses of the 
appropriate isotype and possibly subclass to facilitate both the innate and adaptive 
cellular responses. Although further work is required to verify its role in protection, 
ADCC provides a plausible mechanism for the role of antibody in B. pseudomallei 
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infection, enabling the killing of bacteria during the extracellular phase of infection and . 
targeting of infected cells once the infection becomes intracellular. It also offers an 
explanation for the previously demonstrated protection in passive transfer studies, in 
which the greatest levels of protection against B. pseudomallei were achieved when 
using IgG 1 monoclonal antibodies to the exopolysaccharide (EPS), as compared to 
other monoclonal antibodies against EPS (IgG2a and IgG2b), LPS (IgG2a) and protein 
(IgG2a and IgG3) (112). In addition, data presented in this study highlights a potential 
relationship between immunoglobulin isotype and subclass and protection. This 
suggests that further work to ascertain whether such a correlation is also apparent in 
survivors of B. pseudomallei infection might be appropriate to aid future therapeutic 
and diagnostic efforts. 
Although mechanisms for the intracellular survival of B. pseudomallei are yet to be 
elucidated (62,111), these data, together with other studies (88,177), demonstrate the 
potential importance of an effective CMI response both in controlling infection and 
achieving bacterial clearance following survival of the primary infective phase. Further 
work is still required to fully elucidate the role of T cells in protection, although data 
form this study does support the work of Bancroft and colleagues (88) who suggests a 
role for CD 4+ T cells. In addition a potential role for CD 8+ T cells is suggested by the 
data, most likely mediated through cytotoxic effector function or the secretion of IFN-y. 
However the data from this study does not answer the question as to whether this role is 
essential for survival following B. pseudomallei infection. 
Finally, DC are a heterogeneous population consisting of distinct subsets with common 
as well as unique functions (152). This plasticity of function and unique capacity to 
induce and regulate immune responses makes them an attractive target not only as 
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vectors for the delivery of immunogenic antigens, but also as in vivo targets for immune 
modulation (152). The data presented demonstrates the suitability of DC as a delivery 
vector capable of generating effective CMI responses against intracellular bacteria. 
While this is not the first time this has been demonstrated, it does show the effective 
application of this technology to a pathogen capable of causing significant morbidity 
and mortality to which there is currently no licensed vaccine. 
4.7 Future work 
This work has demonstrated the considerable potential of DC as candidates for the 
induction of cellular immune responses, but further work is required to optimise them as 
a delivery vehicle. There are many avenues of investigation such as alternative culture 
methods, different DC subtypes and the type and amount of antigen used for priming, 
which could potentially enable the required immune response to be generated using DC 
alone. 
The drawbacks associated with using DC as vaccine delivery vectors are well published 
(11,17,45,57,58,67,71,87), but there is also significant potential for the use of DC as a 
mechanism for the evaluation of potential vaccine candidates. Further investigation of 
the protective immune response to B. pseudomallei infection is also perhaps warranted 
especially with regard to the different roles of humoral and cell-mediated immunity. In 
particular, the role and functionality of CD 4+ T cells and of different immunoglobulin 
isotypes and subclasses in protection against infection requires further elucidation. 
Such information would likely provide an effective platform for future rational vaccine 
design against B. pseudomallei. 
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